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Abbreviations 
 
 
Ac  acetyl 
ANP  atrial natriuretic peptide 
APC  allophycocyanin 
Boc  tert-butoxycarbonyl 
BSA  bovine serum albumin 
t
Bu  tert-butyl 
CD  circular dichroism 
COMU  1-[(1-(Cyano-2-ethoxy-2-oxoethylideneaminooxy)-dimethylamino- 
morpholinomethylene)] methanaminium hexafluorophosphate 
DIPCDI  N,N'-diisopropylcarbodiimide 
DIPEA  N,N-diisopropylethylamine 
DMAP  4-(dimethylamino)pyridine 
DMEM  Dulbecco’s modified Eagle’s medium 
DMF  N,N-dimethylformamide 
EDT  1,2-ethanedithiol 
EDTA  ethylenediaminetetraacetic acid 
ESI-TOF electrospray ionization-time-of-flight 
Et  ethyl 
FACS  fluorescence activated cell sorting 
Fmoc  9-fluorenylmethoxycarbonyl 
Fr  fragment 
GFP  green fluorescent protein 
Gn·HCl  guanidine·hydrochloride 
HATU O-(7-aza-1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium 
hexafluorophosphate 
HBTU O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium 
hexafluorophosphate 
HEPES  4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HEPPS  3-[4-(2-hydroxyethyl)piperazin-1-yl]propane-1-sulfonic acid 
HOBt  1-hydroxybenzotriazole 
HPLC  high-performance liquid chromatography 
HRMS  high resolution mass spectrometry 
IR  infrared spectroscopy 
ivDde  1-(4,4-dimethyl-2,6-dioxocyclohexylidene)-3-methylbutyl 
MBHA  4-methylbenzhydrylamine 
MBom  methoxybenzyloxymethyl 
Me  methyl 
MeCN  acetonitrile 
MeONH2·HCl methoxyamine·hydrochloride 
MPAA  4-mercaptophenylacetic acid 
MS  mass spectrometry 
NCL  native chemical ligation 
NMP  N-methylpyrrolidone 
NMR  nuclear magnetic resonance 
PBS  phosphate buffered saline 
SEAlide  N-sulfanylethylanilide 
SPPS  solid-phase peptide synthesis 
TCEP·HCl tris(2-carboxyethyl)phosphine·hydrochloride 
Tf  trifluoromethanesulfonyl 
TFA  trifluoroacetic acid 
THF  tetrahydrofuran 
Thz  thiazolidine carboxylate 
TMS  trimethylsilyl 
Trt  triphenylmethyl 
UV  ultraviolet 
 
The commonly used one- and three- abbreviations for amino acids: 
 
A (Ala)  Alanine 
C (Cys)  Cystein 
D (Asp)  Aspartic acid 
E (Glu)  Glutamic acid 
F (Phe)  Phenylalanine 
G (Gly)  Glycine 
H (His)  Histidine 
I (Ile)  Isoleucine 
K (Lys)  Lysine 
L (Leu)  Leucine 
M (Met)  Methionine 
N (Asn)  Asparagine 
P (Pro)  Proline 
Q (Gln)  Glutamine 
R (Arg)  Arginine 
S (Ser)  Serine 
T (Thr)  Threonine 
V (Val)  Valine 
W (Trp)  Tryptophan 
Y (Tyr)  Tyrosine 
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Figure. Structure of CXCL14 (PDB ID codes 2HDL). 
Preface 
Chemokines are signaling proteins that have important roles in both innate and 
adaptive immune systems. They function as chemoattractants to induce the migration of 
immune cells dependent on their concentration. Some chemokines are involved in 
angiogenesis, tumor metastasis, bacterial infection and other pathological phenomenon. 
For example, CXCL12 is a CXC-type chemokine and is related to tumor growth, 
metastasis, and HIV infection. Therefore, regulation of the CXCL12 signaling pathway 
by CXCR4, a CXCL12 receptor, would be an attractive therapeutic strategy for cancer 
and AIDS. AMD3100 is a CXCR4 antagonist that inhibits the CXCL12-CXCR4 
signaling pathway, and has been approved by the FDA for patients of non-Hodgkin’s 
lymphoma and multiple myeloma. CXCL14 is another variant of the CXC-type 
chemokine and is involved in immunosurveillance, suppression of tumor growth, 
exacerbation of obese diabetes and prevention of bacterial infection. Compared with 
other chemokines, there have been relatively few studies of CXCL14 presumably 
because of a lack of knowledge regarding its receptors and modulators of its functions. 
This study attempted to chemically synthesize CXCL14 and its derivatives for the 
development of molecules to modulate CXCL14 activities and to identify CXCL14 
receptors. 
In Chapter 1, the syntheses of CXCL14 and its derivatives by C–to–N- or N–
to–C- directive sequential native chemical ligation are described. Biological evaluation 
of these proteins revealed that CXCL14 binds to CXCR4 and inhibits the 
CXCL12-induced chemotaxis of CXCR4-expressing THP-1 cells. In Chapter 2, dimer 
peptides derived from the CXCL14 C-terminal region were developed as novel peptide 
inhibitors of the CXCL12-CXCR4 signaling axis. The structure-activity relationship of 
the peptide inhibitors was also studied. Findings obtained in this study suggest that our 
modulator of CXCL14 activity might be a potential novel therapeutic agent that targets 
the CXCL12-CXCR4 signaling axis. 
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Chapter 1 
Synthesis of CXCL14 via C–to–N- or N–to–C-directive 
sequential native chemical ligation 
 
1.1 CXCL14: a binder for CXCR4 and an inhibitor for the CXCL12-CXCR4 
signaling axis 
 
CXCL14 was initially isolated as a novel chemokine in 1999 by Hromas et al. 
from normal breast and kidney tissues and whose expression was down-regulated in 
cancer cell lines (Figure 1. 1).
1
 
 
Although various functions of CXCL14, such as immunosurveillance,
2
 tumor 
suppression,
3
 metabolic regulation
4
 and blocking of microbial infection,
5
 have been 
revealed, receptors of CXCL14 have remained obscure. We recently reported that 
CXCL14 binds to CXCR4, a CXCL12 receptor, expressed on THP-1 cells, with high 
affinity and inhibits CXCL12-mediated chemotaxis.
6
 This suggests that CXCR4 is a 
potential receptor for CXCL14, which is a natural inhibitor of the CXCL12-CXCR4 
signaling axis. Based on this observation, we attempted to develop a molecular probe by 
the chemical syntheses of CXCL14 and its derivatives to further investigate the detailed 
involvement of CXCL14 in the CXCL12-CXCR4 signaling axis. 
 
1.2 Chemical syntheses of CXCL14 and its derivatives using sequential native 
chemical ligation in a C–to–N- or N–to–C-directive manner and their 
biological evaluation 
 
For the chemical synthesis of peptides and proteins,
 
native chemical ligation (NCL) is 
the most widely used ligation method (Scheme 1. 1).
7
 It enables chemoselective ligation 
between a thioester and an N-terminal cysteine residue. Although conventional NCL is 
applicable to the binding of two peptide fragments such as peptide thioester and 
Figure 1.1. The primary aminoacid sequence of CXCL14 
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N-terminal cysteinyl peptide, and provides small proteins of about 80–100 residues, the 
NCL-mediated condensation of more than two fragments to produce middle sized 
proteins over 100 residues is difficult to achieve. The requirement of more than two 
fragments for the synthesis of the middle-sized proteins is attributed to the fact that the 
reliability of solid-phase peptide synthesis (SPPS) for fragment preparation is generally 
limited to proteins to 40 residues in size. Furthermore, the difficulty in achieving this by 
NCL is explained by the use of an N-terminal cysteinyl thioester fragment as a middle 
fragment. That is, the cysteinyl thioester fragment has an intrinsic tendency to be 
converted to a cyclic peptide via intramolecular NCL (Scheme 1. 2-a). Therefore, 
special concern is required when performing NCL using more than two fragments.
8
 One 
potential method is to use C–to–N-directive sequential NCL using an N and/or 
S-protected N-terminal cysteinyl thioester as a middle fragment, which facilitates the 
diversification of the N-terminal portion of target proteins (Scheme 1. 2-b). 
Alternatively, diversification of the C-terminal portion is more easily achieved by use of 
N–to–C-directive sequential NCL (Scheme 1. 2-c). 
To synthesize various CXCL14 proteins possessing diversity in the N- or 
C-terminal portion, we developed a three-fragment sequential NCL protocol using either 
the C–to–N- or N–to–C-directive sequential NCL with an N-terminal protected 
cysteinyl peptide thioester or N-terminal cysteinyl peptide thioacid as a middle fragment, 
respectively.
9
 CXCL14 was divided into three fragments (Fr), 1–28, 29–49 and 50–77 
(termed N-terminal Fr, middle Fr and C-terminal Fr, respectively) and the fragments 
were assembled in both C–to–N and N–to–C directions. 
 
Scheme 1. 1. Native chemical ligation (NCL) to assemble two unprotected peptide fragments. 
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Scheme 1. 2. N-Terminal cysteinyl peptide thioester required for sequential NCL using more than two 
fragments. (a) N-Terminal cysteinyl peptide thioester causes undesired intramolecular NCL. (b) Protection of the 
N-terminal cysteine residue in the middle fragment is required for C–to–N-directive sequential NCL. PGS: 
protecting group of thiol; PGA: protecting group of amine. (c) N-terminal unprotected cysteinyl thioester 
precursor is used as the middle fragment for N–to–C-directive sequential NCL. X: an auxiliary that produces a 
corresponding peptide thioester. 
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In the C–to–N-directive strategy, N-terminal Fr 1 and N-terminal thiazolidine 
carboxylic peptide thioester 2 as middle Fr were prepared using standard 
tert-butoxycarbonyl (Boc)-SPPS  (Scheme 1. 3 and Figure 1. 2). For the preparation of 
C-terminal Fr 3 standard 9-fluorenylmethoxycarbonyl (Fmoc)-SPPS was employed. The 
first NCL of middle Fr 2 and C-terminal Fr 3 proceeded within 4 h in 6 M 
guanidine·HCl (Gn·HCl)-0.2 M sodium phosphate buffer (pH 6.8) containing 1% (v/v) 
thiophenol to produce the desired ligated product. Then, 0.2 M 
methoxyamine·hydrochloride (MeONH2·HCl) was added to the mixture to open the 
thiazolidine ring and produce the N-terminal unprotected ligation product 4. After 
HPLC purification, 4 was subsequently ligated with N-terminal Fr 1 in 6 M Gn·HCl-0.2 
M sodium phosphate buffer (pH 6.8) containing 1% (v/v) thiophenol. After completion 
of the second NCL, the reduced form of CXCL14 (CXCL14 (4-Cys)) 5 was isolated by 
HPLC purification. The resulting CXCL14 (4-Cys) 5 was subjected to a refolding 
procedure under air oxidation conditions
10
 in 3 M Gn·HCl-0.1 M sodium phosphate 
buffer (pH 7.7) and the desired folded human CXCL14 6 was obtained after purification 
 
Scheme 1. 3. Synthesis of human CXCL14 (6) in the C–to–N direction. (i) First NCL in 6 M Gn·HCl-0.2 M 
sodium phosphate buffer (pH 6.8) in the presence of 1% (v/v) thiophenol. (ii) Addition of 0.2 M MeONH2·HCl 
to open the thiazolidine ring. (iii) Second NCL in 6 M Gn·HCl-0.2 M sodium phosphate buffer (pH 6.8) in the 
presence of 1% (v/v) thiophenol. (iv) Oxidation with air in 3 M Gn·HCl-0.1 M sodium phosphate buffer (pH 
7.7). R = -(CH2)2-CO-Ala-NH2. 
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by HPLC in 13% overall yield (3 steps). 
In the initial attempt of N–to–C-directive strategy, an N-terminal cysteinyl 
thioacid was employed as the middle fragment because the N-terminal cysteinyl moiety 
does not react intramolecularly with the thioacid as a latent thioester unit (Scheme 1. 4 
and Figure 1. 3).
7, 11
 Middle Fr 7 was prepared according to a method developed by our 
group.
12
 Briefly, the protected N-sulfanylethylanilide (SEAlide)
13
 peptide of CXCL14 
(29–49) with an N-terminal Fmoc group was synthesized on aminomethyl ChemMatrix 
resin using standard Fmoc-SPPS, and the acid-labile protecting groups on side chains 
were removed
 
by treatment with TFA/thioanisole/m-cresol/H2O/1,2-ethanedithiol 
(EDT)/Et3SiH (80:5:5:5:5:5 (v/v)). The resulting peptide-attached resin was then treated 
with 4 M HCl/DMF in the presence of 1% (w/v) tris(2-carboxyethyl)phosphine 
hydrochloride (TCEP·HCl) to give the corresponding peptide thioester resin via 
on-resin-intramolecular N–S acyl transfer. Treatment of the thioester resin with 120 mM 
NaSH in 6 M Gn·HCl-0.1 M sodium phosphate buffer (pH 9.2) provided the peptide 
thioacid, which was then converted to the middle Fr 7 by piperidine-mediated Fmoc 
removal. The mutation of H49G was incorporated because of the instability of thioester 
species derived from histidyl thioacid moieties. The first NCL of N-terminal Fr 1 and 
middle Fr 7 in 6 M Gn·HCl-0.2 M sodium phosphate buffer (pH 6.8) containing 1% 
(v/v) thiophenol at 37 °C provided the ligated thioacid 8 (Scheme 1. 4 and Figure 1. 3). 
During the first NCL, the intramolecular NCL product was not observed. 
HPLC-purified thioacid 8 was then treated with an excess amount of Ellman’s reagent14 
in the presence of KHCO3 in 20% (v/v) DMF aq. to afford peptide thioesters. Then, the 
cysteine residues were converted to the disulfide species by the action of Ellman’s 
Figure 1. 2. HPLC monitoring of the C–to–N directive sequential NCL for synthesis of human CXCL14 
(6). (a) First NCL (t < 1 min). (b) First NCL (t = 4 h) followed by addition of 0.2 M MeONH2·HCl. (c) 
Second NCL (t < 1min). (d) Second NCL (t = 6 h). (e) Oxidation (t = 6.5 h). HPLC conditions: Cosmosil 
5C18 AR-II column (4.6 × 250 mm) with a linear gradient of 0.1% TFA-MeCN/0.1% TFA aq. (5:95–45:55 
over 30 min) at a flow rate of 1.0 mL/min, detection at 220 nm. 
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reagent. To reduce the resulting disulfide species, and more importantly to quench the 
excess Ellman’s reagent that inhibits successive NCL, TCEP·HCl, a reducing agent, was 
added to the reaction mixture to yield desired thioester 9. Then, C-terminal Fr 3 and 1% 
(v/v) thiophenol was added to the mixture at 37 °C to initiate the second NCL. The 
second NCL was completed within 2 h, and following HPLC purification, it produced 
CXCL14 (4-Cys, H49G) 10. The obtained peptide 10 was folded under air oxidation 
conditions in 3 M Gn·HCl-0.1 M sodium phosphate buffer (pH 7.7) to obtain folded 
CXCL14 (H49G) 11. After completion of the folding, CXCL14 (H49G) 11 was purified 
by HPLC and was obtained in 1% overall yield (3 steps). The inhibitory activities of 
synthetic CXCL14 proteins 6 and 11 to CXCL12-mediated chemotaxis were evaluated 
by standard chemotaxis assays using human leukemia-derived THP-1 cells (Figure 1. 
4).
15
 The number of THP-1 cells in the upper chamber in the presence of 100 nM 
CXCL14 that migrated toward the lower chamber containing 10 nM CXCL12 was 
counted. Both synthetic CXCL14 proteins 6 and 11 showed inhibitory activity against 
CXCL12-mediated chemotaxis comparable with that of recombinant one. As mentioned 
here, synthetic CXCL14 proteins obtained by the conventional C–to–N- and N–to–
C-directive protocols undoubtedly afforded biologically active materials; however, the 
Scheme 1. 4. Synthesis of CXCL14 (H49G) (11) in N–to–C direction. (i) First NCL in 6 M Gn·HCl-0.2 M 
sodium phosphate buffer (pH 6.8) in the presence of 1% (v/v) thiophenol. (ii) Thioesterification by treatment 
with Ellman’s reagent and KHCO3 in 20% (v/v) DMF aq., then addition of TCEP·HCl. (iii) Second NCL in 
20% DMF aq. in the presence of 1% (v/v) thiophenol. (iv) Oxidation with air in 3 M Gn·HCl-0.1 M sodium 
phosphate buffer (pH 7.7). R = -(CH2)2-CO-Ala-NH2. 
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chemical yield of the N–to–C-directive method was unsatisfactory. Therefore, an 
efficient N–to–C-directive method is urgently required in the field of chemical protein 
synthesis. In this context, we attempted to develop an N-sulfanylethylanilide (SEAlide) 
peptide-mediated N–to–C-directive strategy for efficient CXCL14 preparation. 
 
 
  
Figure 1. 3. HPLC monitoring of the N–to–C directive sequential NCL for the synthesis of CXCL14 
(H49G) (11). (a) First NCL (t < 1 min). (b) First NCL (t = 4 h). (c) Thioesterification of thioacid 8 to 
corresponding aryl thioester 9 by treatment with Ellman’s reagent and KHCO3 in 20% (v/v) DMF aq. for 1 h 
followed by the addition of TCEP·HCl. (d) Second NCL (t < 1 min): addition of C-terminal fragment 3 to 
the thioesterification reaction mixture and then, the pH of the mixture was adjusted to approximately 7.5. (e) 
Second NCL (t = 2 h). (f) Oxidation (t = 22 h). HPLC conditions: Cosmosil 5C18 AR-II column (4.6 × 250 
mm) with a linear gradient of 0.1% TFA-MeCN/0.1% TFA aq. (5:95–45:55 over 30 min) at a flow rate of 
1.0 mL/min, detection at 220 nm. *DMF. **5-mercapto-2-nitrobenzoic acid. 
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1.3 One-pot/sequential native chemical ligation strategy for syntheses of 
CXCL14 and its derivatives using N-sulfanylethylanilide peptide 
 
 We previously reported the use of three-fragment/one-pot sequential NCL for 
the synthesis of human atrial natriuretic peptide (ANP) using an N-terminal cysteinyl 
SEAlide peptide as a middle fragment (Scheme 1. 5).
16
 The sequential NCL was 
achieved by controlling the reactivity of the SEAlide peptide that functions as a 
thioester equivalent only in the presence of phosphate salts. To achieve a greater 
efficiency, we applied the SEAlide peptide as a middle fragment for the synthesis of 
CXCL14 using the one-pot method (Scheme 1. 6). To prepare the middle fragment, 
Fmoc-histidine-coupled N-sulfanylethylaniline linker, 
4-[{Fmoc-His(Fmoc)-2-tritylsulfanylethyl}amino]benzoic acid 14 was synthesized as 
shown in Scheme 1. 7. The protection of the histidyl imidazole group is associated with 
its racemization during the coupling of histidine species with the aniline linker 15. We 
found that an Fmoc group on a -nitrogen atom of the imidazole (Fmoc-His(Fmoc)-OH) 
suppressed the racemization comparable with that of a previously reported 
methoxybenzyloxymethyl (MBom) group on the -nitrogen atom of the imidazole.17  
Figure 1. 4. Inhibitory activity of CXCL14 proteins to CXCL12-mediated chemotaxis. The cell number of 
THP-1 cells that migrated toward 10 nM CXCL12 in the absence or presence of 100 nM CXCL14 proteins was 
counted (n = 3). Data are shown as the chemotactic index: the migrated cell number to CXCL12 divided by 
migrated cell number to medium alone. **P < 0.01 compared with the PBS (upper)/CXCL12 (lower) control. 
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The incorporation of Fmoc-Ala-OH onto NovaSyn® TGR resin and subsequent 
coupling of compound 14 with the resulting resin were achieved to give the SEAlide 
unit-incorporated resin. The protected peptide chain was elongated on the resin by 
s t an d a r d  Fm o c  S P P S .  T h e  co m p l e t ed  r e s i n  w as  d ep r o t ec t e d  w i t h 
TFA-thioanisole-m-cresol-EDT-H2O (80:5:5:5:5, v/v) at room temperature for 1.5 h, and 
the resulting TFA mixture was cooled to 0 °C. Ammonium iodide (NH4I) and dimethyl 
sulfide (Me2S) were subsequently added to the mixture to reduce the methionine oxide 
formed during chain elongation.
18
 The desired SEAlide peptide 12 was obtained by 
HPLC purification. Once the requisite fragments for the construction of CXCL14 were 
obtained, the synthesis of CXCL14 by one-pot/sequential NCL method using the 
SEAlide peptide as a middle fragment was attempted. The first NCL between 
 
Scheme 1. 5. The character of N-sulfanylethylanilide (SEAlide) peptide and its application. (a) SEAlide 
peptide as a peptide thioester equivalent in the presence of phosphate salts. (b) A SEAlide peptide is applicable 
to one-pot sequential NCL by controlling concentration of phosphate salts. 
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N-terminal Fr 1 and middle Fr 12 was conducted at 25 °C in 6 M Gn·HCl-0.2 M 
HEPPS buffer (pH 6.6), 50 mM MPAA and 30 mM TCEP·HCl, and then C-terminal Fr 
3 in 1 M sodium phosphate buffer (pH 6.6) was added to the mixture to initiate the 
second NCL (Figure 1. 5). The N–to–C-directive one-pot/sequential strategy yielded 
reduced CXCL14 5 in 38% isolated yield. The resulting CXCL14 (4-Cys) 5 was 
oxidized as described in a previous section to give folded CXCL14 6 in 39% isolated 
yield. This method successfully improved the overall yield (15%, 2 steps), compared 
with the N–to–C-directive sequential NCL using peptide thioacid mentioned above (1%, 
3 steps). The reason for this improvement might be explained by the easy experimental 
manipulations and reduction of the number of purification step when using the one-pot 
procedure. Next, we attempted to develop a molecular probe based on CXCL14 to 
investigate the involvement of CXCL14 in the CXCL12-CXCR4 signaling axis using 
sequential NCL strategies. Initially, CXCL14 derivative 26 possessing an Alexa fluor® 
488 hydroxyamine 25 moiety on its C-terminal portion was prepared using the 
Scheme 1. 6. Synthesis of human CXCL14 (6) by N–to–C directive one-pot/sequential NCL using SEAlide 
peptide. (i) First NCL in 6 M Gn·HCl-0.2 M HEPPS buffer (pH 6.6), 50 mM MPAA and 30 mM TCEP·HCl, 
then (ii) addition of C-terminal fragment 3 in 1 M sodium phosphate buffer (pH 6.6), (second NCL). (iii) 
Oxidation with air in 3 M Gn·HCl-0.1 M sodium phosphate buffer (pH 7.7). R = -(CH2)2-CO-Ala-NH2. 
 
12 
 
conventional C–to–N-directive strategy (Scheme 1. 8 and 1. 9). To conjugate CXCL14 
and Alexa fluor® 488 by oxime linkage, we initially synthesized a dialdehyde linker 
19.
19
 p-Formylbenzoic acid 17 was coupled with O,O’-bis(3-aminopropyl)diethylene 
glycol 18 to afford dialdehyde linker 19. Then, CXCL14 derivative 23 possessing an 
Figure 1. 5. HPLC monitoring of the N–to–C directive one-pot/sequential NCL for synthesis of human 
CXCL14 (6). (a) First NCL (t < 1 min) in 6 M Gn·HCl-0.2 M HEPPS buffer (pH 6.6), 50 mM MPAA and 30 
mM TCEP·HCl. (b) First NCL (t = 5 h). (c) followed by addition of C-terminal fragment 3 in 1 M sodium 
phosphate buffer (pH 6.6) (second NCL, t < 1 min). (d) Second NCL (t = 48 h) (e) Oxidation with air (t = 23 h). 
HPLC conditions: Cosmosil 5C18 AR-II column (4.6 × 250 mm) with a linear gradient of 0.1% 
TFA-MeCN/0.1% TFA aq. (5:95–45:55 over 30 min) at a flow rate of 1.0 mL/min, detection at 220 nm. 
 
Scheme 1. 7. Synthesis of Fmoc-His(Fmoc)-SEAlide linker 14. (a) SOCl2, cat. DMF, CH2Cl2, r.t., then removal 
of the solvent in vacuo. The obtained crude mixture without purification was reacted with sodium amide in THF 
that was afforded in step (b). (b) NaH, THF, r.t.. (c) N-methylaniline, Pd(PPh3)4, THF, r.t., 65% (2 steps) 
13 
 
additional lysine residue at the C-terminus was synthesized. A side chain amino group 
of the additional residue was modified by an aminooxyacetyl group to conjugate the 
aldehyde unit of linker 19. The requisite aminooxyacetylated fragment 20 was prepared 
by Fmoc SPPS using N

-ivDde-protected lysine followed by on-resin-selective 
deprotection of ivDde and coupling of Boc-aminooxyacetic acid with the resulting 
N

-amino group. Fragment couplings using C-terminal Fr 20 bearing 
aminooxyacetylated lysine at its C-terminus were performed by conventional C–to–
N-directive NCL similar to that employed for CXCL14 6. Resulting linear protein 22 
was folded under air-oxidation conditions to give the folded CXCL14 derivative 23, 
which was then treated with an excess amount of linker 19 in 6 M Gn·HCl-0.1 M 
sodium phosphate buffer (pH 5.8) and 0.5 mM EDTA to generate linker-incorporated 
CXCL14 derivative 24 through oxime bond formation. After completion of the reaction, 
excess linker 19 was washed out by CH2Cl2 extraction, and then Alexa fluor® 488 
hydroxyamine 25 in 6 M Gn·HCl-0.1 M sodium phosphate buffer (pH 4.0) and 0.5 mM 
EDTA was subsequently added to the mixture to afford the desired Alexa fluor® 
488-incorporated CXCL14 derivative 26. Unfortunately, synthesized derivative 26 was 
not suitable for practical use in fluorescent imaging due to its low fluorescence intensity. 
Therefore, a CXCL14 derivative with a biotin unit (CXCL14-K(biotin)) 29, which is 
highly fluorescent upon treatment with streptavidin-fluorescent (allophycocyanin 
(APC)) conjugate, was synthesized by the SEAlide peptide-mediated N–to–C-directive 
one-pot/sequential NCL method similar to that employed for CXCL14 6 using 
C-terminal Fr 27 with additional C-terminal biotinylated lysine residue (Scheme 1. 10). 
Requisite biotinylated fragment 27 was synthesized by an Fmoc protocol similar to that 
employed for 20. The N–to–C-directive one-pot/sequential NCL followed by folding 
successfully produced the desired biotinylated CXCL14 analog 29 that was fluorescent 
with the aid of a streptavidin-APC conjugate. Next, we attempted to confirm the binding 
of CXCL14-K(biotin) 29 to CXCR4. 
Scheme 1. 8. Synthesis of dialdehyde linker 19. (a) DIPCDI, DMAP, CH2Cl2, r.t., 84% 
14 
 
  
Scheme 1. 9. Synthesis of human CXCL14-K(Alexa Fluor® 488) 26 (i) First NCL in 6 M Gn·HCl-0.1 M 
sodium phosphate buffer (pH 6.8) and 0.5 mM EDTA in the presence of 1% (v/v) thiophenol. (ii) Addition of 
0.2 M MeONH2·HCl to open the thiazolidine ring. (iii) Second NCL in 6 M Gn·HCl-0.1 M sodium phosphate 
buffer (pH 6.8) and 0.5 mM EDTA in the presence of 1% (v/v) thiophenol. (iv) Oxidation with air in 3 M 
Gn·HCl-0.1 M sodium phosphate buffer (pH 7.7). (v) Oxime ligation in 6 M Gn·HCl-0.1 M sodium phosphate 
buffer (pH 5.8) and 0.5 mM EDTA, then excess linker 19 was washed out by CH2Cl2. (vi) Addition of Alexa 
Fluor® 488 hydroxyamine in 6 M Gn·HCl-0.1 M sodium phosphate buffer (pH 4.0) and 0.5 mM EDTA to the 
resulting crude solution of 24. R = -(CH2)2-CO-Ala-NH2. 
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1.4 Biological evaluation of the biotinylated CXCL14 derivative 
 
To confirm whether biotinylated CXCL14 29 maintained its inhibitory activity 
for CXCL12-mediated cell migration, standard chemotaxis assays using THP-1 cells 
were conducted (Figure 1. 6). CXCL14-K(biotin) 29 exhibited an inhibitory activity 
comparable with that of the expressed and chemically synthesized CXCL14. This 
suggests that the biotin derivative 29 could be used as a molecular probe to evaluate the 
binding potency of CXCL14. The binding of CXCL14-K(biotin) 29 to CXCR4 was 
assessed by fluorescence activated cell sorting (FACS) analysis using human cervical 
carcinoma-derived HeLa cells transfected with a pCS2+GFP vector for HeLa-GFP cells 
or a pCS2+CXCR4-GFP vector for HeLa-CXCR4-GFP cells (Figure 1. 7). Initially, to 
 
Scheme 1. 10. Synthesis of CXCL14-K(biotin) (29) in N–to–C directive one-pot/sequential NCL using 
SEAlide peptide. (i) First NCL in 6 M Gn·HCl-0.2 M HEPPS buffer (pH 6.6), 50 mM MPAA and 30 mM 
TCEP·HCl, then (ii) addition of C-terminal fragment 27 in 1 M sodium phosphate buffer (pH 6.6), (second 
NCL). (iii) Oxidation with air in 3 M Gn·HCl-0.1 M sodium phosphate buffer (pH 7.7). R = 
-(CH2)2-CO-Ala-NH2. 
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confirm the expression of CXCR4, these cells were analyzed by FACS analysis using 
APC-conjugated anti-human CXCR4 antibody (anti-CXCR4-APC) (Figure 1. 7-a, b). 
The expression of CXCR4 on HeLa-GFP cells was slightly detected due to the presence 
of endogenous CXCR4 on the cells (Figure 1. 7-a). In HeLa-CXCR4-GFP cells, the 
expression level of CXCR4 was markedly enhanced (Figure 1. 7-b). Thus, we evaluated 
the binding of CXCL14-K(biotin) 29 to CXCR4 on these HeLa cell lines by FACS 
analysis and found that CXCL14-K(biotin) 29 had potent binding to HeLa-GFP cells 
(Figure 1. 7-c) and a higher binding potency to HeLa-CXCR4-GFP cells (Figure 1. 7-d). 
In the presence of high concentrations of unlabeled CXCL14, the binding of 
CXCL14-K(biotin) 29 to the cells was significantly reduced (Figure 1. 7-c, d). These 
results proved that CXCL14-K(biotin) 29 specifically binds to CXCR4 on HeLa cells. 
The reason for the partial inhibition of binding by excess CXCL14 might be explained 
by the presence of low affinity binding site for basic CXCL14 such as heparan sulfate 
on the cell surface.
20
 
 
1.5 Conclusion 
 
A synthetic platform for CXCL14 was developed using C–to–N- or N–to–
C-directive sequential NCL protocols. In particular, the N–to–C-directive protocol using 
a SEAlide peptide as a middle fragment allowed one-pot sequential ligation with easy 
Figure 1. 6. Inhibitory activity of CXCL14 proteins to CXCL12-mediated chemotaxis. Numbers of migrating 
THP-1 cells toward 10 nM CXCL12 in the absence or presence of 100 nM CXCL14 proteins were counted (n = 
3). Data are shown as the chemotactic index: the migrated cell number to CXCL12 divided by migrated cell 
number to the medium alone (PBS/BSA). **P < 0.01 compared to the (PBS/BSA)/CXCL12 control. 
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experimental manipulations. This protocol provided better results in overall yield and 
purity than the protocol employing a peptide thioacid which required multi-step 
manipulation and intermediate purification. The binding experiment of biotinylated 
CXCL14 derivative 29 against CXCR4-expressing HeLa cells clearly indicated that 
CXCL14 binds to CXCR4, a receptor for CXCL12. 
Figure 1. 7. (a, b) FACS analysis of CXCR4 expression (a) HeLa-GFP cells or (b) fusion protein of CXCR4 
and GFP (HeLa-CXCR4-GFP). Anti-CXCR4-APC bound on the cells was detected by FACS analysis. The 
cells were untreated (red) or treated with anti-CXCR4-APC (blue), respectively. (c, d) FACS analysis of 
CXCL14-K(biotin) 29 binding (c) HeLa-GFP or (d) HeLa-CXCR4-GFP. CXCL14-K(biotin) bound on the 
cells was stained with APC-streptavidin, and then detected by FACS analysis. The cells were treated with 100 
nM biotin (red), 100 nM CXCL14-K(biotin) 29 (blue) or 100 nM CXCL14-K(biotin) 29 + 4 M CXCL14 
(green), respectively. 
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Chapter 2 
Development of a novel inhibitor of the CXCL12-CXCR4 
signaling axis 
 
2.1 Exploration of the interaction region of CXCL14 with CXCR4 
Figure 2. 1. Competitive binding assay of CXCL14 derivatives. (a) Synthesized CXCL14 derivatives. (b) 
Competitive inhibition of 125I-CXCL14 binding by CXCL14 derivatives. CXCR4 transfected THP-1 cells were 
incubated with 10 nM 125I-CXCL14 in the presence or absence of 100 nM CXCL14 derivatives, and 
cell-associated radioactivity was measured (n = 6). Relative binding of 125I-CXCL14 to no competitor is shown. 
*P < 0.05, **P < 0.01 compared with no competitor, respectively. 
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Most CXC-type chemokines possess flexible N-terminal regions that are 
important for their receptor binding,
21
 whereas CXCL14 lacks a corresponding region. 
Therefore, we hypothesized that CXCL14 binds to its receptor in a manner different 
from other CXC-type chemokines, presumably using a C-terminal -helical region. To 
investigate the critical region of CXCL14 that is involved in interaction with CXCR4, 
the binding affinities of various CXCL14-derived peptides, listed in Figure 2. 1, were 
evaluated. The binding potency of CXCL14-derived peptides was examined by 
competitive inhibition of 
125
I-labeled CXCL14 (
125
I-CXCL14) binding using CXCR4 
transfected THP-1 cells (Figure 2. 1b).
15
 Middle fragment-deleted analog 32 without 
folded structure (i.e. reduced form) showed binding affinity to CXCR4-expressing cells 
comparable with that of CXCL14. Furthermore, C-terminal Fr 36 also showed binding 
potency to CXCR4-expressing cells, whereas middle Fr 30 and CXCL14-CXCL12 
chimera 34 with CXCL14 (51–77) replaced by CXCL12 (50–72) did not show any 
binding inhibition. These results suggested that the C-terminal -helical region of 
CXCL14 (CXCL14 (51–77)) was essential for binding to CXCR4 expressing THP-1 
cells. This region is highly conserved among numerous species from elephant shark to 
humans and possesses unique conserved aromatic amino acid residues on one surface of 
the -helix (Figure 2. 2).22 In our recent study, chemical crosslinking experiments of 
CXCR4 on THP-1 cells with CXCL14 indicated that a dimeric form of CXCL14 is 
associated with the interaction with CXCR4 in addition to the monomeric form.
6
 It was 
also reported that other chemokines such as CXCL8 and CXCL12 form homodimers 
that have unique activities.
23
 Therefore, we attempted to synthesize and evaluate 
dimeric peptides of this region. 
Figure 2. 2. Structure of the CXCL14 (50–77) (PDB ID codes 2HDL). Aromatic residues are shown. 
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2.2 Synthesis and biological evaluation of a dimerized CXCL14 C-terminal 
fragment 
 
Initially, a disulfide dimer peptide of CXCL14 C-terminal Fr 3 (termed N2C 
37) was synthesized (Scheme 2. 1). The abbreviation “N2C” represents a 
cystine-containing (C) dimerized (2)-native sequence (N). C-Terminal Fr 3, the 
synthetic intermediate requisite for the preparation of CXCL14 as an N-terminal 
cysteinyl fragment, was incubated in 0.1 M sodium phosphate buffer (pH 7.7, peptide 
concentration: 1 mM) to form an intermolecular disulfide bond and N2C 37 was 
obtained after HPLC purification (Figure 2. 3). Of note, N2C 37 showed competitive 
inhibition of the binding of I
125
-CXCL14 to CXCR4 and inhibitory activity of 
CXCL12-mediated chemotaxis that was comparable with that of CXCL14 (Figure 2. 4). 
 
 
 
 
Scheme 2. 1. Synthesis of the disulfide dimer N2C 37. 
Figure 2. 3. HPLC monitoring of the synthesis of N2C 37. (a) Disulfide bond formation (t < 1 min). (b) 
Disulfide bond formation (t = 12 h). HPLC conditions: Cosmosil 5C18 AR-II column (4.6 × 250 mm) with a 
linear gradient of 0.1% TFA-MeCN/0.1% TFA aq. (5:95–45:55 over 30 min) at a flow rate of 1.0 mL/min, 
detection at 220 nm. 
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2.3 Synthesis and biological evaluation of the dimer of mutated CXCL14 
C-terminal fragment 
 
N2C 37 is considered to form an -helical structure and its characteristic 
structure is likely to be responsible for its inhibitory activity against CXCL12-induced 
chemotaxis through its CXCR4 binding. Thus, we speculated that the -helicity of 
peptides would be relevant to inhibitory potency.
24
 Furthermore, the -helical wheel 
representation of the CXCL14 C-terminal region shows that conserved aromatic 
residues accumulate on one -helical face composed of a, d and e positions (Figure 2. 2, 
2. 5). This prompted us to envision that an appropriate positioning of such aromatic 
 
Figure 2. 4. Biological evaluation of N2C 37. (a) Competitive inhibition of 125I-CXCL14 binding by N2C 37. 
CXCR4 transfected THP-1 cells were incubated with 10 nM 125I-CXCL14 in the presence or absence of 100 
nM competitors, and cell-associated radioactivity was measured (n = 6). Relative binding of 125I-CXCL14 to no 
competitor is shown. (b) Inhibition activity of N2C 37 against CXCL12-mediated chemotaxis. Numbers of 
migrating THP-1 cells toward 10 nM CXCL12 in the absence or presence of 100 nM CXCL14 derivatives were 
counted (n = 3). Data are shown as the chemotactic index: the migrated cell number to CXCL12 divided by 
migrated cell number to the medium alone (PBS). *P < 0.05, **P < 0.01 compared with no competitor or 
PBS/CXCL12, respectively. 
Figure 2. 5. Helical wheel representation of C-terminal portion of CXCL14 (54-77). 
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residues on one face of an -helix would be responsible for CXCR4-binding and 
inhibitory activity. Taking these speculations into consideration, we attempted to 
incorporate a substitution of Glu and Lys in an i to i+4 relationship manner for b,f, c,g 
or f,c pairing (termed b,f-EK, c,g-EK or f,c-EK, respectively) (Table 2. 1).
24
 
Incorporation of Glu-Lys pairing in i to i+4 relationship has been well documented to 
enhance -helicity of peptides through intrahelical salt bridge formation.25 
Additionally, limited substitutions to b, c, f, and g positons was thought to 
result in the appropriate positioning of the aromatic residues in a, d, and e positions. 
Disulfide bridge-formed dimer peptides (BF2C 38 (b,f-EK), CG2C 40 (c,g-EK) and 
FC2C 42 (f,c-EK): substitution pattern is shown in parenthesis) were synthesized by a 
Table 2. 1. Synthesized mutants of N2C 37. 
Figure 2. 6. Biological evaluation of mutants of N2C 37. (a) Competitive inhibition of 125I-CXCL14 binding by 
mutants of N2C 37. CXCR4 transfected THP-1 cells were incubated with 10 nM 125I-CXCL14 in the presence 
or absence of 100 nM competitors, and cell-associated radioactivity was measured (n = 6). Relative binding of 
125I-CXCL14 to no competitor is shown. (b) Inhibition activity of the mutants of N2C 37 to CXCL12-mediated 
chemotaxis. Numbers of migrating THP-1 cells toward 10 nM CXCL12 in the absence or presence of 100 nM 
CXCL14 derivatives were counted (n = 3). Data are shown as chemotactic index: the migrated cell number to 
CXCL12 divided by migrated cell number to the medium alone (PBS). *P < 0.05, **P < 0.01 compared with no 
competitor or PBS/CXCL12, respectively. 
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method similar to that employed for N2C 37. Biological evaluations of synthetic 
materials were performed by a competitive binding assay using the CXCR4-transfected 
THP-1 cells and 
125
I-CXCL14 and a standard chemotaxis assay (Figure 2. 6). Among 
the mutated peptides, CG2C 40 functioned as the most effective competitive binder and 
antagonized CXCL12-induced chemotaxis with an efficacy similar to that of native 
CXCL14 or N2C 37. CD measurement of synthetic peptides indicated that CG2C 40  
had the best-organized -helical structure (Figure 2. 7). Furthermore, mutated peptides 
containing the substitution of Glu and Lys for g and d (GD2C 44), d and a (DA2C 46), 
a and e (AE2C 48) or e and b (EB2C 50) showed no significant inhibiting activity 
against CXCL12-mediated chemotaxis (Table 2. 2 and Figure 2. 8). These results 
suggested that the accumulation of aromatic residues (F61, W64, Y65, W68) on the 
Figure 2. 7. CD spectrum of dimer peptides. 
 
Table 2. 2. Synthesized mutants of N2C 37 with mutation of a, d and e-positions.. 
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-helical surface through helix formation is an indispensable event for the antagonistic 
activity of CXCL14 against the CXCL12-CXCR4 signaling axis. 
As mentioned above, although N2C 37 and CG2C 40 are effective inhibitors of 
the CXCL12-CXCR4 signaling axis, physiological instability due to the presence of the 
Figure 2. 8. Inhibition activity of the mutated dimers to CXCL12-mediated chemotaxis. Numbers of 
migrating THP-1 cells toward 10 nM CXCL12 in the absence or presence of 100 nM CXCL14 derivatives 
were counted (n = 3). Data are shown as chemotactic index: the migrated cell number to CXCL12 divided by 
migrated cell number to the medium alone (PBS). **P < 0.01 compared with PBS/CXCL12. 
 
Scheme 2. 2. Synthesis of the oxime dimers 53 and 55. Excess amounts of the monomer peptide were 
incubated with linker 19 in 6 M Gn·HCl-0.1 M sodium phosphate buffer (pH 7.6) and 0.05 mM EDTA. 
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disulfide bridge is an issue. Thus, we planned to synthesize a new type of dimer 
connected by oxime linkage. The oxime bond is more stable under physiological 
conditions compared with the disulfide bond.
26
 Dimers with oxime linkage were 
successfully synthesized using dialdehyde linker 19 and N-terminal additional 
aminooxyacetyl group on the monomeric peptide (Scheme 2. 2). Oxime versions (53 
and 55) corresponding to disulfide dimers N2C 37 and CG2C 40, respectively, were 
synthesized as shown below. Incubation with an excess amount of the N-terminal 
aminooxyacetylated C-region peptides (52 and 54) in the presence of aldehyde linker 19 
in 6 M Gn·HCl-0.1 M sodium phosphate buffer (pH 7.6) and 0.05 mM EDTA, followed 
by HPLC purification, yielded oxime dimers 53 and 55 corresponding to N2C 37 and 
CG2C 40, respectively (Scheme 2. 2 and Figure 2. 9). The abbreviations including O 
Figure 2. 9. HPLC monitoring of the synthesis of N2O 53. (a) Oxime ligation (dimerization) (t < 1 min). (b) 
Oxime ligation (dimerization) (t = 3 h). HPLC conditions: Cosmosil 5C18 AR-II column (4.6 × 250 mm) with a 
linear gradient of 0.1% TFA-MeCN/0.1% TFA aq. (5:95–45:55 over 30 min) at a flow rate of 1.0 mL/min, 
detection at 220 nm. 
 
Figure 2. 10. Biological evaluation of oxime dimers. (a) Competitive inhibition of 125I-CXCL14 binding by 
oxime dimers. CXCR4 transfected THP-1 cells were incubated with 10 nM 125I-CXCL14 in the presence or 
absence of 100 nM competitors, and cell-associated radioactivity was measured (n = 6). Relative binding of 
125I-CXCL14 to no competitor is shown. (b) Inhibition activity of oxime dimers to CXCL12-mediated 
chemotaxis. Numbers of migrating THP-1 cells toward 10 nM CXCL12 in the absence or presence of 100 nM 
CXCL14 derivatives were counted (n = 3). Data are shown as chemotactic index: the migrated cell number to 
CXCL12 divided by migrated cell number to the medium alone (PBS). **P < 0.01 compared with no 
competitor or PBS/CXCL12. 
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instead of C, such as N2O 53 and CG2O 55, were used to indicate oxime linkage (O). 
The binding potency and inhibitory activity of the oxime dimers were assessed by 
competitive binding assay and standard chemotaxis assay similar to those employed for 
disulfide dimers (Figure 2. 10). CG2O 55 showed a binding potency to CXCR4 
expressing THP-1 cells and inhibitory activity to CXCL12-mediated chemotaxis 
comparable with that of N2C 37. Next, the IC50 value of inhibition of 
125
I-CXCL14 
binding to THP-1 cells expressing CXCR4 was determined (Figure 2. 11). The IC50 
value of CG2O 55 was 4.9 nM, and was superior to that of CXCL14 (11.5 nM) and 
N2C 37 (14.9 nM), whereas, the IC50 value of monomer peptide 36 and monomer 
peptide with mutation c,g-EK 56 were 51.0 nM and 161.1 nM, respectively. These data 
demonstrated the importance of dimerization of C-terminal fragments for inhibitory 
activity. Furthermore, to confirm the importance of dimerization, we synthesized a 
trimer of the CXCL14 C-terminal fragment 57 (Scheme 2. 3). Excess amounts of 
monomer peptide 52 were incubated with the commercially available trialdehyde linker 
58 in 6 M Gn·HCl-0.1 M sodium phosphate buffer (pH 5.5) and 0.5 mM EDTA. After 
completion of the reaction, trimer 57 was purified by HPLC. Evaluation of inhibitory 
activity of trimer 57 to CXCL12-mediated chemotaxis and measurement of its CD 
spectrum revealed that trimerization of this fragment was not effective either inhibitory 
Figure 2. 11. Effective competition of 125I-CXCL14 binding by (a) a disulfide dimer and (b) an oxime dimer 
mutated to c,g-EK. CXCR4 transfected THP-1 cells were incubated with 10 nM 125I-CXCL14 in the presence of 
various concentration of competitors, and cell-associated radioactivity was measured (n = 4 (a) and n = 3 (b), 
respectively). Relative binding of 125I-CXCL14 to no competitor is shown. (c) Calculated IC50 values of the 
CXCL14 derivatives. 
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activity or the formation of an -helix structure (Figure 2. 12). 
 
 
 
 
 
 
 
Scheme 2. 3. Synthesis of a trimer of CXCL14 C-terminal Fr. Excess amounts of monomer peptide 52 were 
incubated with linker 58 in 6 M Gn·HCl-0.1 M sodium phosphate buffer (pH 5.5) and 0.5 mM EDTA. 
 
Figure 2. 12. (a) Inhibition activity of trimer 57 to CXCL12-mediated chemotaxis. Numbers of migrating 
THP-1 cells toward 10 nM CXCL12 in the absence or presence of 100 nM CXCL14 derivatives were counted 
(n = 3). Data are shown as chemotactic index: the migrated cell number to CXCL12 divided by migrated cell 
number to the medium alone (PBS). *P< 0.05 compared to PBS/CXCL12. (b) CD spectrum of the trimer 57. 
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2.4 Identification of dimer peptide residues indispensable for inhibitory activity 
to CXCL12-mediated chemotaxis 
 
As mentioned in a previous section, both the presence of aromatic residues in a, 
d and/or e positions of -helix and the dimerization are likely to be essential for the 
antagonistic activity of the CXCL14-derived peptide against CXCL12-CXCR4 axis. To 
obtain more precise information about the relationship between the a, d and e-residues 
and the inhibitory activity, single mutations on the aromatic residues of a, d or e 
position were performed. Dimer peptides 59 (W64A, from 60), 61 (Y65A, from 62), 63 
(W68A, from 64), and 65 (Y75A, from 66) were synthesized using a method similar to 
Table 2. 3. Synthesized disulfide dimer with aromatic amino acid residues mutated to alanine. 
Figure 2. 13. Inhibition activity of mutated dimers to CXCL12-mediated chemotaxis. Numbers of migrating 
BaF/3 cells toward 10 nM CXCL12 in the absence or presence of 100 nM CXCL14 derivatives were counted 
(n = 3). Data are shown as chemotactic index: the migrated cell number to CXCL12 divided by migrated cell 
number to the medium alone (PBS). *P < 0.05, **P < 0.01 compared with PBS/CXCL12, respectively. 
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that for N2C 37 (Table 2. 3). In comparison with N2C 37, the singly mutated peptides 
did not show a significant difference in inhibitory activity against CXCL12-mediated 
chemotaxis (Figure 2. 13). This indicated the cooperative involvement of aromatic 
residues in inhibitory activity. Although an evaluation of the cooperative involvement of 
aromatic residues was required, we next planned to synthesize deletion peptides sets 
from the C-terminal (residue 77) and N-terminal (residue 52) ends of the CXCL14 
C-terminal region. Two series of deletion mutants from the C and N ends, listed in Table 
2. 4 and 2. 5, were prepared as their disulfide dimer forms. Evaluation of the inhibitory 
activity of the deletion sets are summarized in Figure 2. 14 (for C end deletion) and 
Figure 2. 15 (for N end deletion). Regarding the deletion mutants from the N end (109, 
111, 113 and 115), there were solubility problems that precluded the use of these 
peptides for biological evaluation. Consequently, a one- to five-residue deletion from 
the C end and one-residue deletion from the N-end were acceptable for maintenance of 
inhibitory activity. From these results, we tentatively concluded that residues 52–72 
might function as a core sequence indispensable for inhibitory activity. Indeed, disulfide 
dimer peptide 117 covering residues 52–72 retained an inhibitory activity comparable 
with that of N2C 37 (Figure 2. 16). 
Because the shorted C-terminal analog 117 had an inhibitory activity 
comparable with that of parent N2C 37, we incorporated a combinatorial substitution of 
Ala for aromatic residues (F61, W64, Y65 and/or W68) to explore their cooperative  
Table 2. 4. Synthesized disulfide dimers with deletion of the sequence from the C-terminus. 
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Figure 2. 14. Inhibition activity of the disulfide dimers deleted the sequence of CXCL14 C-terminal Fr from 
C-terminus to CXCL12-mediated chemotaxis. Numbers of migrating THP-1 cells toward 10 nM CXCL12 in the 
absence or presence of 100 nM CXCL14 derivatives were counted (n = 3). Data are shown as chemotactic index: 
the migrated cell number to CXCL12 divided by migrated cell number to the medium alone (PBS). *P < 0.05, 
**P < 0.01 compared with PBS/CXCL12, respectively. 
 
Table 2. 5. Synthesized disulfide dimers with deletion of the sequence from N-terminus. 
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Figure 2. 15. Inhibition activity of the disulfide dimers deleted the sequence of CXCL14 C-terminal Fr from 
N-terminus to CXCL12-mediated chemotaxis. Numbers of migrating THP-1 cells toward 10 nM CXCL12 in 
the absence or presence of 100 nM CXCL14 derivatives was counted (n = 3). Data are shown as chemotactic 
index: the migrated cell number to CXCL12 divided by migrated cell number to the medium alone (PBS). *P < 
0.05 compared with PBS/CXCL12. 
 
Figure 2. 16. Inhibition activity of the disulfide dimer of CXCL14 (52-72) to CXCL12-mediated chemotaxis. 
Numbers of migrating THP-1 cells toward 10 nM CXCL12 in the absence or presence of 100 nM CXCL14 
derivatives were counted (n = 3). Data are shown as chemotactic index: the migrated cell number to CXCL12 
divided by migrated cell number to the medium alone (PBS). *P < 0.05, **P < 0.01 compared with 
PBS/CXCL12. 
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Table 2. 6. Synthesized disulfide dimers with mutation of aromatic amino acid residues to alanine. 
Figure 2. 17. Inhibition activity of the disulfide dimer of CXCL14 (52-72) with mutation of aromatic amino 
acid residues to alanine to CXCL12-mediated chemotaxis. Numbers of migrating THP-1 cells toward 10 nM 
CXCL12 in the absence or presence of 100 nM CXCL14 derivatives were counted (n = 4). Data are shown as 
chemotactic index: the migrated cell number to CXCL12 divided by migrated cell number to the medium alone 
(PBS). *P < 0.05 compared with no competitor (PBS/PBS) and not significant compared with PBS/CXCL12. 
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involvement in the inhibitory activity. Evaluation of these peptides by chemotaxis assay 
revealed that peptides (125: W64A, Y65 and W68A and 141: F61A, W64A, Y65A and 
W68A) possessing multi Ala-mutations did not retain the inhibitory potency (Figure 2. 
17).  
Evaluation of these peptides by chemotaxis assay revealed that three aromatic 
residues (W64, Y65 and W68) functioned in a coordinated manner to provide the 
inhibitory activity. In terms of the inhibitory role of the amino acids located in b, c, f or 
g positions, pairwise substitution of Glu and Lys for b and f resulted in a significant 
decrease in inhibitory activity as mentioned in section 2.3 (Figure 2. 6). However, such 
mutations at c and g positions did not affect the inhibitory activity. Thus, we next 
examined whether only single set of mutations (b or f only) was acceptable for 
maintenance of the inhibitory activity. Biological evaluation of analogs of dimer peptide 
 
Table 2. 7. Synthesized disulfide dimers with mutation of b- or f-position to alanine. 
Figure 2. 18. Inhibition activity of the disulfide dimer of CXCL14 (52-72) with mutation of the b- or 
f-position to alanine to CXCL12-mediated chemotaxis.Numbers of migrating THP-1 cells toward 10 nM 
CXCL12 in the absence or presence of 100 nM CXCL14 derivatives were counted (n = 3). Data are shown 
as chemotactic index: the migrated cell number to CXCL12 divided by migrated cell number to the 
medium alone (PBS). *P < 0.05 compared with no competitor (PBS/PBS) and not significant compared 
with PBS/CXCL12. 
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117 possessing a replacement of b- (143) or f-residues (145) with Ala showed that these 
peptides retained their inhibitory activity (Table 2. 7, Figure 2. 18). These results 
indicate that the three aromatic residues in a, d and e-positions are critical for inhibitory 
activity against CXCL12-mediated chemotaxis. Additionally, b- and f-residues were 
proven to function in a cooperative manner to affect the inhibitory activity to a lesser 
extent than aromatic residues. 
 
2.5 Conclusion 
 
Competitive binding assay of various monomeric reduced-type 
CXCL14-derived peptides to CXCR4 expressing THP-1 cells using 
125
I-CXCL14 
indicated that the C-terminal region within residues 50–77 was indispensable for 
binding of CXCL14 to THP-1 cells expressing CXCR4. Taking into consideration the 
fact that chemokine molecules have a tendency to form dimer species through 
non-bonding protein/protein interactions, we attempted to synthesize dimer analogs 
derived from CXCL14 (50–77) to examine the effect of dimerization on binding to 
CXCR4 expressing THP-1 cells including the inhibitory activity against the 
CXCL12-CXCR4 signaling axis. Disulfide dimer N2C 37 possessing a native 
C-terminal sequence could bind to CXCR4 expressing cells and inhibit 
CXCL12-mediated chemotaxis with an efficiency comparable with the parent CXCL14. 
An -helical structure consisting of one -helical surface (a, d and e residues) with the 
accumulation of highly conserved aromatic residues prompted us to incorporate 
pairwise Glu-Lys substitutions in an i to i+4 manner for residues in the other -helical 
surface (b, c, f and g residues) to enhance CXCR4 binding and inhibitory activity. The 
salt bridge forming Glu-Lys substitution was expected to contribute to an appropriate 
arrangement of the conserved aromatic residues by increasing the -helicity of mutated 
analogs. Among the synthesized derivatives, CG2O 55 with a c,g-EK substitution 
pattern and oxime-dimer structure showed a binding affinity slightly superior to 
CXCL14. The critical involvement of the aromatic residues in CXCL12-mediated 
chemotaxis was demonstrated using C-terminal dimer analogs with a shorter sequence 
and/or replacement of Ala with aromatic residues. Chemotaxis assays using these 
analogs showed that three aromatic residues (W64, Y65 and W68) are indispensable 
residues for inhibitory activity.  Additionally, biological evaluation of b- and/or 
f-residue mutated dimer peptides indicated that these residues are also cooperatively 
involved in the inhibitory activity. 
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Chapter 3 
Conclusions 
 
1.  The Syntheses of CXCL14 and its derivatives were achieved by C–to–
N- or N–to–C-directive sequential NCL methods using protected N-terminal 
cysteinyl (N-Cys) peptide thioester (C–to–N), unprotected N-Cys peptide 
thioacid (N–to–C) or unprotected N-Cys SEAlide peptide (N–to–C) as the 
middle fragment, respectively. In particular, the use of SEAlide peptide as the 
middle fragment enabled us to synthesize CXCL14 in a one-pot manner with 
easy experimental manipulation. Biological evaluation of the synthetic 
CXCL14 proteins indicated that they exhibited inhibitory activity against 
CXCL12-mediated chemotaxis comparable with that of recombinant CXCL14. 
Furthermore, binding of biotinylated CXCL14 to HeLa cells expressing 
CXCR4 was also confirmed by FACS analysis. 
  Findings in this study demonstrate that the use of sequential NCL 
methods in both C–to–N and N–to–C directions for the synthesis of CXCL14 
enables the easy preparation of various CXCL14 derivatives including biotin- 
and fluorophore-incorporated CXCL14. As mentioned above, CXCR4 was 
shown to function as a cell surface binder for CXCL14; however, the 
identification of a putative receptor for CXCL14 has yet to be achieved. The 
next goal for CXCL14 research should be the identification of potential 
CXCL14 receptor(s) that are responsible for mediating the physiological 
effects of CXCL14. 
 
2  Evaluation of various peptides derived from CXCL14 revealed that 
CXCL14 binds to THP-1 cells expressing CXCR4 by the C-terminal -helical 
region 51-77, and that the disulfide dimer of this region functions as an 
inhibitor of the CXCL12-CXCR4 signaling axis. Biological activity of mutated 
dimers, in which substitutions of glutamic acid (E) and lysine (K) in i and i+4 
positions were incorporated to enhance their -helicity, was also evaluated. The 
evaluation of these mutated dimers suggested that one -helical surface (a, d 
and e) where aromatic residues (F61, W64, Y65 and W68) were accumulated 
are essential for the inhibitory activity. In addition, a dimer peptide with a 
substitution of pairwise Glu and Lys mutations for c and g positions did not 
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affect the inhibitory activity, whereas dimers with such a substitution for b and 
f or f and c positions decreased the inhibitory activity. Cooperative involvement 
of the aromatic residues was confirmed using shortened mutants derived from 
CXCL14 52-72 residues. The indispensability of this sequence for inhibitory 
activity was determined by deletion experiments. As a result, it was revealed 
that three aromatic residues (W64, Y65 and W68) are essential for the 
inhibitory activity and that they function cooperatively 
Information about which residues are indispensable for the function of 
CXCL14 and their special arrangement on an -helix structure should provide 
a platform for the design of small molecule CXCL14 mimics. Extensive efforts 
along these lines are currently underway in our laboratory. 
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Experimental section 
 
General Methods 
All reactions of small molecules were carried out under a positive pressure of 
argon. For column chromatography, silica gel (KANTO KAGAKU N-60, Kanto 
Chemicals, Tokyo, Japan) was employed. Thin layer chromatography was performed on 
precoated plates (0.25 nm, silica gel Merck Kieselgel 60F245). Exact mass spectra were 
recorded on Waters MICROMASS LCT PREMIER. Nuclear magnetic resonance 
(NMR) spectra were recorded using a Bruker AV400N at 400 MHz frequency for 
1
H 
and a JEOL JNM-AL300 at 75 MHz frequency for 
13
C in CDCl3. Chemical shifts were 
calibrated to the solvent signal. For HPLC separations, a Cosmosil 5C18-AR-II 
analytical column (Nacalai Tesque, 4.6 × 250 mm, flow rate 1 mL/min), a 5C18-AR-II 
semi-preparative column (Nacalai Tesque, 10 × 250 mm, flow rate 3.0 mL/min) or a 
5C18-AR-II preparative column (Nacalai Tesque, 20 × 250 mm, flow rate 10 mL/min) 
was employed, and eluting products were detected by UV at 220 nm. A solvent system 
consisting of 0.1% TFA aqueous solution (v/v, solvent A) and 0.1% TFA in MeCN (v/v, 
solvent B) was used for HPLC elution. IR spectra and optical rotations were recorded 
with FT-IP 6200 (Jasco, Tokyo, Japan) and P-2200 polarimeter (Jasco, concentration in 
g/100 mL), respectively. Circular dichroism (CD) spectra were measured using a J-600 
spectropolarimeter (Jasco) and a J-1500 (Jasco). Far-UV CD spectra were recorded 
from 185 to 265 nm at 25 °C (peptide concentration: 50 g/mL). 
All reagents that were used for chemical synthesis were purchased from either 
Kanto Chemicals, Sigma Aldrich Japan, Tokyo Chemical Industry, Wako Pure Chemical 
Industries, Peptide Institute, Inc., Watanabe Chemical Industry or Novabiochem. 
Peptide Synthesizer CS336 (CS Bio Co., Menlo Park, CA, USA) was used for 
automatic peptide synthesis. 
THP-1 was obtained from the Human Science Research Resource Bank 
(JCRB0112) and maintained at 37 °C in RPMI-1640 medium (Sigma, Tokyo, Japan) 
containing 10% fetal calf serum (FCS) (Invitrogen, Life Technologies Japan, Tokyo, 
Japan), 0.5% penicillin-streptomycin (Sigma), and 50 M -mercaptoethanol (Sigma). 
Hela S3 cells were maintained at 37 °C in DMEM medium (Sigma) containing 10% 
FCS, 0.5% penicillin-streptomycin. Recombinant human CXCL14 and human CXCL12 
were purchased from PeproTech (Rocky Hill, NJ, USA). BSA and HEPES were 
obtained from Sigma and Invitrogen, respectively. In chemotaxis assays, chemotaxicell 
filters (5 m pore size; Kurabo, Osaka, Japan) and Diff-Quik stain (Sysmex, Kobe, 
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Japan) were used. 
Bolton-Hunter reagent and WIZARD2 gamma counter were obtained from 
Perkin Elmer. Borate buffer (0.1 M, pH 8.2) containing 0.01% Tween 20 was purchased 
from Nacalai Tesque. For separation of 
125
I-labeled CXCL14, D-Salt polyacrylamide 
desalting column (Pierce) was employed. BSA and HEPES were obtained from Sigma 
and Invitrogen, respectively. GraphPad Prism (GraphPad Software) was used for 
calculating dissociation constants of the binding assays. 
 
Chapter 1 
 
Preparation of CXCL14 N-terminal fragment 1 
On 4-methylbenzhydrylamine (MBHA) resin (0.70 mmol amine/g), 
introduction of Boc-Ala-OH (5.0 equiv) in the presence of DIPCDI (5.0 equiv) and 
HOBt·H2O (5.5 equiv) in DMF at room temperature for 2 h followed by Boc removal 
by TFA/anisole/toluene (50:2:48 (v/v), 15 min) afforded the Boc-Ala-incorporated resin. 
Next, treatment of the resulting resin with S-Trt mercaptopropionic acid (5 equiv),
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DIPCDI (5.0 equiv), HOBt·H2O (5.5 equiv) and DIPEA (2.0 equiv) in DMF at room 
temperature for 2 h followed by Trt removal by TFA/Et3SiH/H2O (95:2.5:2.5 (v/v), 5 
min) gave HS-CH2CH2CO-Ala-MBHA resin. Activated Boc-His(Bom)-OH (5.0 equiv) 
with HBTU (4.8 equiv) and DIPEA (6.8 equiv) in DMF was coupled with the 
HS-CH2CH2CO-Ala-MBHA resin for 3 h, and the resin was subsequently subjected to 
Boc removal by TFA/anisole/toluene (50:2:48 (v/v), 15 min). On the resulting resin, 
standard in situ neutralization Boc SPPS (Acylation: Boc amino acid (5.0 equiv), 
DIPEA (2.0 equiv.), DIPCDI (5.0 equiv) and HOBt·H2O (5.5 equiv) in DMF for 2 h; 
Boc removal: TFA/anisole/toluene (50:2:48 (v/v), 20 min) was performed for the chain 
elongation to give protected peptide resin for N-terminal Fr 1.
28
 The resulting completed 
resin (100 mg) was treated with 1 M TMSOTf-thioanisole in TFA and m-cresol (100:5 
(v/v)) at 4 
o
C for 2 h, and then the mixture was warmed to room temperature and stirred 
at this temperature for 30 min. The reaction mixture was then cooled to 4 
o
C, and NH4I 
(75 equiv) and Me2S (75 equiv) were added to the mixture. The mixture was stirred at 4 
o
C for 30 min for reduction of methionine oxide formed during chain elongation. After 
filtration of the reaction mixture into cooled Et2O, the resulting precipitate was collected 
by centrifugation. The obtained precipitate was washed with cold Et2O and purified by 
preparative HPLC to give peptide thioester 1 (11 mg, 26%). 
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N-Terminal Fr 1: Analytical HPLC condition: linear gradient of solvent B in 
solvent A, 5 to 45% over 30 min, retention time = 15.5 min. Preparative HPLC 
condition: linear gradient of solvent B in solvent A, 13 to 23% over 30 min. MS 
(electrospray ionization-time-of-flight (ESI-TOF)) m/z calcd for [M + 4H]
4+
 874.0, 
found 873.5. 
 
Preparation of CXCL14 middle fragment 2 
 Middle Fr 2 was synthesized using the Boc SPPS in a manner similar to that 
employed for N-terminal Fr 1. 
Middle Fr 2 (5.1 mg from 100 mg resin, 10%): Analytical HPLC condition: 
linear gradient of solvent B in solvent A, 5 to 45% over 30 min, retention time = 19.5 
min. Preparative HPLC condition: linear gradient of solvent B in solvent A, 15 to 25% 
over 30 min. MS (ESI-TOF) m/z calcd for [M + 3H]
3+
 888.8, found 888.7. 
 
Preparation of CXCL14 C-terminal fragment 3 
The protected peptide resin was constructed on Fmoc-Glu(O
t
Bu)-Alko-PEG 
resin (loading: 0.24 mmol amino acid/g) using standard Fmoc SPPS (Acylation: Fmoc 
amino acid (5.0 equiv), DIPCDI (5.0 equiv) and HOBt·H2O (5.5 equiv) in DMF for 2 h; 
Fmoc removal: 20% (v/v) piperidine in DMF for 10 min). The completed resin (100 
mg) was treated with TFA-thioanisole-m-cresol-H2O-1,2-ethanedithiol (EDT) 
(80:5:5:5:5, (v/v)) at room temperature for 1.5 h. After filtration of the resin, cooled 
Et2O was added to the filtrate, and the resulting precipitate was collected by 
centrifugation. The obtained precipitate was washed with cold Et2O and purified by 
preparative HPLC to give C-terminal Fr 3 (24 mg, 62%). 
C-Terminal Fr 3: Analytical HPLC condition: linear gradient of solvent B in 
solvent A, 5 to 45% over 30 min, retention time = 23.8 min. Preparative HPLC 
condition: linear gradient of solvent B in solvent A, 20 to 30% over 30 min. MS 
(ESI-TOF) m/z calcd for [M + 4H]
4+
 906.5, found 906.5. 
 
Synthesis of CXCL14 6 using C–to–N-directive sequential NCL 
The First NCL: N-Terminal thiazolidine carboxylic (N-Thz) peptide thioester 2 
(1.5 mg, 0.57 mol) as middle Fr and N-terminal cysteine (N-Cys) peptide 3 (2.1 mg, 
0.57 mol) as C-terminal Fr were dissolved in 6 M Gn·HCl-0.2 M sodium phosphate 
buffer (pH 6.8) containing 1% (v/v) thiophenol to initiate the first NCL (Final 
concentration of each peptides: 1.0 mM). After completion of the reaction by incubation 
at 37 °C for 4 h, methoxyamine·hydrochloride (MeONH2·HCl) was added directly to 
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the ligation reaction mixture at a final concentration of 0.2 M. The opening of Thz ring 
to convert to Cys was completed within 2 h. The crude material was purified by 
semi-preparative HPLC to afford ligated peptide 4 (2.6 mg, 76%). 
The Second NCL: N-Terminal Fr 1 (0.95 mg, 0.27 mol) and the ligated 
product 4 (1.7 mg, 0.27 mol) were dissolved in 6 M Gn·HCl-0.2 M sodium phosphate 
buffer (pH 6.8) containing 1% (v/v) thiophenol (Final concentration of each peptides: 
1.0 mM). After disappearance of the starting materials 1 and 4 by incubation of the 
mixture at 37 °C for 6 h, the crude material was purified by semi-preparative HPLC to 
give reduced form CXCL14 5 (CXCL-14 (4-Cys)). Oxidation of the purified 5 with air 
was performed in 3 M Gn·HCl-0.1 M sodium phosphate buffer (pH 7.7, concentration 
of the peptide: 0.050 mM).
10
 After incubation of the mixture at 37 °C for 8 h, CXCL14 
6 (0.34 mg, 17%, 2 steps) was isolated by semi-preparative HPLC. 
CXCL14 (29-77) 4: Analytical HPLC condition: linear gradient of solvent B in 
solvent A, 5 to 45% over 30 min, retention time = 23.6 min. Semi-preparative HPLC 
condition: linear gradient of solvent B in solvent A, 15 to 45% over 30 min. MS 
(ESI-TOF) m/z calcd for [M + 4H]
4+
 1525.3, found 1525.2.
 
CXCL14 (4-Cys) 5: Analytical HPLC condition: linear gradient of solvent B in 
solvent A, 5 to 45% over 30 min, retention time = 21.7 min. Semi-preparative HPLC 
condition: linear gradient of solvent B in solvent A, 20 to 28% over 30 min. MS 
(ESI-TOF) m/z calcd for [M + 11H]
11+
 856.7, found 856.9. 
CXCL14 6: Analytical HPLC condition: linear gradient of solvent B in solvent 
A, 5 to 45% over 30 min, retention time = 21.1 min. Semi-preparative HPLC condition: 
linear gradient of solvent B in solvent A, 19 to 29% over 30 min. MS (ESI-TOF) m/z 
calcd for [M + 10H]
10+
 941.9, found 941.9. 
 
Preparation of CXCL14 middle fragment (H49G) 7 with peptide thioacid moiety 
On aminomethyl ChemMatrix resin (1.0 mmol amine/g) was coupled 
Fmoc-Ala-OH (5.0 equiv) in the presence of DIPCDI (5.0 equiv) and HOBt·H2O (5.5 
equiv) in DMF at room temperature for 2 h, and then the resulting resin was treated with 
20% (v/v) piperidine in DMF for 10 min for Fmoc removal. Next, treatment of the 
resulting resin with Fmoc-Gly-incorporated N-sulfanylethylaniline linker (2 equiv),
13
 
HATU (1.9 equiv), and DIPEA (2.0 equiv) in DMF at room temperature for 2 h 
followed by Fmoc removal by 20% (v/v) piperidine in DMF for 10 min afforded the 
SEAlide linked resin. On the resulting resin, standard Fmoc SPPS mentioned above was 
performed for the chain elongation to give protected peptide resin. Deprotection of the 
completed resin with TFA-thioanisole-m-cresol-H2O-EDT-Et3SiH (80:5:5:5:2.5:2.5, 
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(v/v)) at room temperature for 1.5 h followed by the treatment with 4 M HCl/DMF in 
the presense of TCEP·HCl (1% (w/v)) at room temperature for 20 h gave deprotected 
on-resin peptide thioester. The on-resin peptide thioester was incubated with 120 mM 
NaSH in 6 M guanidine-0.1 M sodium phosphate buffer (pH 9.2) at 37 °C for 30 min to 
yield the hydrothiolytically released N

-Fmoc protected peptide thioacid. Then 
piperidine was added to the crude mixture of the Nα-Fmoc protected peptide thioacid, 
and the Fmoc group on the peptide thioacid was completely removed to give crude 
materials which were then subjected to semi-preparative HPLC purification to afford 
the desired middle Fr 7 with peptide thioacid moiety. 
Peptide thioacid 7: Analytical HPLC condition: linear gradient of solvent B in 
solvent A, 5 to 45% over 30 min, retention time = 18.7 min. Semi-preparative HPLC 
condition: linear gradient of solvent B in solvent A, 12 to 27% over 30 min. MS 
(ESI-TOF) m/z calcd for [M + 3H]
3+
 810.7, found 810.7. 
 
Synthesis of CXCL14 (H49G) 11 using N–to–C-directive sequential NCL 
The first NCL: Peptide thioester 1 (2.7 mg, 0.78 mol) and N-Cys peptide 
thioacid 2 (1.8 mg, 0.76 mol) were dissolved at a final concentration of 1 mM in 6 M 
Gn·HCl-0.1 M sodium phosphate buffer and 1% (v/v) thiophenol. After disappearance 
of the starting materials by incubation of the reaction mixture at 37 °C for 2 h, the crude 
material was then purified by semi-preparative HPLC to give ligated peptide thioacid 8 
(1.0 mg, 22%). 
The second NCL: The purified peptide thioacid 8 (0.29 mg, 0.050 mol) was 
dissolved at a final concentration of 1 mM in DMF/H2O (2:8 (v/v)) containing 6 mM 
Ellman’s reagent and 6 mM KHCO3. The resulting mixture was shaken at room 
temperature for 1 h. Then 1% (w/v) TCEP·HCl was added to the reaction mixture to 
reduce an excess Ellman’s reagent and the hetero disulfide resulted from reaction of the 
cysteine sulfhydryl group with 5-mercapto-2-nitrobenzoic acid. The conversion of 
thioacid 8 to thioester 9 was confirmed by HPLC analysis. N-Cys fragment 3 (0.18 mg, 
0.050 mol) and 1% (v/v) thiophenol were added to the reaction mixture and then the 
pH of the reaction mixture was adjust around 7.5 by addition of 10% (w/v) K2CO3 
aqueous solution at 4 °C. After disappearance of the starting materials by incubation of 
the mixture at 37 °C for 2 h, the crude material was purified by semi-preparative HPLC 
to give ligated peptide 10 (0.056 mg, 12%). Oxidation of the purified CXCL14 (H49G, 
4-Cys) 10 (2.26 mg, 2.4 mol) with air was performed in 3 M Gn·HCl-0.1 M sodium 
phosphate buffer (pH 7.7, concentration of the peptide: 0.050 mM). After incubation of 
the mixture at 37 °C for 6 h, CXCL14 (H49G) 11 (0.66 mg, 38%) was isolated by 
42 
 
semi-preparative HPLC. 
Peptide thioacid 8: Analytical HPLC condition: linear gradient of solvent B in 
solvent A, 5 to 45% over 30 min, retention time = 18.7 min. Semi-preparative HPLC 
condition: linear gradient of solvent B in solvent A, 12 to 27% over 30 min. MS 
(ESI-TOF) m/z calcd for [M + 5H]
5+
 1150.0, found 1150.0. 
Peptide thioester 9: Analytical HPLC condition: linear gradient of solvent B in 
solvent A, 5 to 45% over 30 min, retention time = 21.3 min. MS (ESI-TOF) m/z calcd 
for [M + 4H]
4+
 1478.5, found 1478.6. 
CXCL14 (H49G, 4-Cys) 10: Analytical HPLC condition: linear gradient of 
solvent B in solvent A, 5 to 45% over 30 min, retention time = 20.5 min. 
Semi-preparative HPLC condition: linear gradient of solvent B in solvent A, 15 to 45% 
over 30 min. MS (ESI-TOF) m/z calcd for [M + 9H]
9+
 1037.9, found 1038.3. 
CXCL14 (H49G) 11: Analytical HPLC condition: linear gradient of solvent B 
in solvent A, 5 to 45% over 30 min, retention time = 19.3 min. Semi-preparative HPLC 
condition: linear gradient of solvent B in solvent A, 20 to 30% over 30 min. MS 
(ESI-TOF) m/z calcd for [M + 7H]
7+
 1333.7, found 1333.8. 
 
Synthesis of Fmoc-His(Fmoc)-incorporated N-sulfanylethylaniline linker 14 
To a solution of aniline 15 (1.2 g, 2.5 mmol) in tetrahydrofuran (THF) (25 mL) 
was added 55% NaH (120 mg, 2.8 mmol) by portions at room temperature and the 
mixture was stirred at same temperature. In another flask, Fmoc-His(Fmoc)-OH (3.0 g, 
5 mmol) was treated with SOCl2 (3.7 mL, 50 mmol) in CH2Cl2 (60 mL) in the presence 
of catalytic amount of DMF (39 L, 0.5 mmol) at room temperature. After being stirred 
at same temperature for 3 h, the reaction mixture was concentrated under reduced 
pressure. The residue was added to another flask containing THF solution of 15 and 
NaH, and then the mixture was stirred at room temperature overnight. The reaction was 
quenched with saturated NaHCO3 aqueous solution (sat. NaHCO3 aq.) and extracted 
with EtOAc. The organic layer was washed with sat. NaHCO3 aq. followed by brine and 
dried over MgSO4. After removal of the solvent under reduced pressure, the crude 
material was roughly purified by column chromatography on silica gel using 
EtOAc/n-hexane (= 1:2 (v/v)) and gave Fmoc-His(Fmoc)-incorporated linker 16 as a 
white amorphousness. Compound 16 was subsequently treated with N-methylaniline 
(10 equiv) and Pd(PPh3)4 (0.10 equiv) in THF (0.1 M) at room temperature for 2.5 h. 
The solvent was then removed under reduced pressure and the product was purified by 
column chromatography on silica gel using EtOAc/n-hexane (= 1:1 (v/v)) to give 1.7 g 
(65%, 2 steps) of compound 14 as a white amorphousness. 
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Allyl 4-[{Fmoc-His(Fmoc)-2-tritylsulfanylethyl}amino]benzoate 16: []24D 
52.4 (c 1.00, CHCl3); IR (KBr) max, cm
-1
: 703, 743, 1012, 1270, 1405, 1447, 1491, 
1602, 1667, 1723, 1763, 2950, 3020, 3060, 3297; 
1
H-NMR (400 MHz, CDCl3)  = 
2.29-2.35 (m, 1H), 2.50-2.57 (m, 1H), 2.64 (dd, J = 6.4 and 14.8 Hz, 1H), 2.75 (dd, J = 
5.2 and 14.8 Hz, 1H), 3.29-3.36 (m, 1H), 3.51-3.58 (m, 1H), 4.18 (t, J = 7.2 Hz, 1H), 
4.28-4.32 (m, 3H), 4.48-4.49 (m, 1H), 4.66 (d, J = 6.8 Hz, 2H), 4.84 (d, J = 5.6 Hz, 2H), 
5.31 (dd, J = 1.2 and 10.4 Hz, 1H), 5.43 (dd, J = 1.2 and 17.2 Hz, 1H), 5.86 (d, J = 8.4 
Hz, 1H), 6.04 (ddt, J = 5.6, 10.4 and 17.2 Hz, 1H), 7.05-7.19 (m, 12H), 7.27-7.34 (m, 
10H), 7.36-7.44 (m, 4H), 7.53-7.58 (m, 4H), 7.75 (d, J = 7.2 Hz, 2H), 7.78 (d, J = 7.6 
Hz, 2H), 7.91 (s, 1H), 8.04 (d, J = 8.4 Hz, 2H); 
13
C-NMR (75 MHz, CDCl3)  = 29.3, 
30.9, 46.7, 47.2, 49.4, 51.6, 66.0, 67.1, 67.2, 69.9, 114.6, 118.7, 120.1, 120.4, 124.9, 
125.3, 126.8, 127.2, 127.5, 127.8, 128.0, 128.3, 129.6, 130.1, 131.3, 132.1, 136.7, 139.0, 
141.4, 141.5, 142.8, 144.0, 144.6, 145.1, 148.3, 155.7, 165.4, 170.6; high resolution 
mass spectrometry (HRMS) (ESI-TOF) m/z calcd for C67H57N4O7S ([M+H]
+
), 
1061.3948, found 1061.3962. 
4-[{Fmoc-His(Fmoc)-2-tritylsulfanylethyl}amino]benzoic acid 14: []24D 43.9 
(c 1.00, CHCl3); IR (KBr) max, cm
-1
: 703, 742, 760, 1013, 1248, 1404, 1447, 1492, 
1601, 1667, 1723, 1766, 2495, 2621, 2953, 3061, 3292; 
1
H-NMR (400 MHz, CDCl3)  
= 2.27-2.34 (m, 1H), 2.50-2.56 (m, 1H), 2.80 (dd, J = 7.2 and 14.0 Hz, 1H), 2.87-2.92 
(m, 1H), 3.22-3.29 (m, 1H), 3.53-3.60 (m, 1H), 4.19 (t, J = 7.3 Hz, 1H), 4.30 (t, J = 7.0 
Hz, 1H), 4.34 (d, J = 7.3 Hz, 2H), 4.64-4.69 (m, 1H), 4.65 (d, J = 7.0 Hz, 2H), 5.90 (br 
d, J = 8.4 Hz, 1H), 6.97 (br d, J = 6.8 Hz, 2H), 7.08-7.19 (m, 10H), 7.27-7.43 (m, 14H), 
7.54 (d, J = 7.6 Hz, 2H), 7.57-7.59 (m, 2H), 7.73-7.74 (m, 2H), 7.78 (d, J = 7.6 Hz, 2H), 
8.01 (d, J = 8.4 Hz, 2H), 8.24 (s, 1H); 
13
C-NMR (75 MHz, CDCl3)  = 29.2, 31.3, 46.6, 
47.2, 49.4, 51.3, 67.1, 67.3, 70.2, 115.2, 120.1, 120.4, 124.9, 125.3, 126.8, 127.2, 127.6, 
127.8, 128.0, 128.4, 128.6, 128.7, 129.6, 130.6, 131.8, 132.2, 132.3, 137.6, 138.0, 141.4, 
141.4, 142.7, 143.9, 144.3, 144.6, 148.1, 155.7, 167.9, 171.1; HRMS (ESI-TOF) m/z 
calcd for C64H53N4O7S ([M+H]
+
), 1021.3635, found 1021.3633. 
 
Preparation of CXCL14 middle fragment 12 as SEAlide peptide 
The protected peptide resin was constructed on NovaSyn
®
 TGR resin (loading: 
0.25 mmol/g) using Fmoc SPPS (Acylation: Fmoc amino acid (5.0 equiv), DIPCDI (5.0 
equiv) and HOBt·H2O (5.5 equiv) in DMF or 14 (2.0 equiv), HATU (1.95 equiv) and 
DIPEA (1.95 equiv) in DMF for 2 h; Fmoc removal: 20% (v/v) piperidine in DMF for 
10 min). The completed resin (100 mg) was treated with 
TFA-thioanisole-m-cresol-H2O-EDT (80:5:5:5:5, (v/v)) at room temperature for 1.5 h, 
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and then NH4I (75 equiv) and Me2S (100 equiv) were added to the TFA solution at 0 °C. 
After stirring of the mixture at same temperature for 30 min, the resin was filtered off 
and the filtrate was directly added to cold Et2O to generate precipitate. The precipitate 
collected by centrifugation was washed with cold Et2O and purified by preparative 
HPLC to give the middle fragment 12 (8.2 mg, 18%). 
SEAlide peptide 12: Analytical HPLC conditions, linear gradient of solvent B 
in solvent A, 5 to 45% over 30 min, retention time = 18.6 min. Preparative HPLC 
condition: linear gradient of solvent B in solvent A, 15 to 23% over 30 min. MS 
(ESI-TOF) m/z calcd for [M + 3H]
3+
 915.1, found 914.9. 
 
Synthesis of CXCL14 6 using N–to–C-directive one-pot/sequential NCL with the 
use of the SEAlide peptide 
The first NCL between N-terminal Fr 1 (1.7 mg, 0.35 μmol as 1·12TFA) and 
SEAlide peptide 12 (1.2 mg, 0.35 μmol as 12·6TFA) was performed in 6 M Gn·HCl-0.2 
M HEPPS buffer containing 50 mM MPAA and 30 mM TCEP·HCl (pH 6.6, 347 L, 1 
mM each peptide) at 25 °C. The reaction was completed within 5 h. Then, C-terminal Fr 
3 solution (1.6 mg, 0.35 mol as 3·9TFA) in 1 M sodium phosphate buffer (pH 6.6, 347 
L) was added to the reaction mixture. The second NCL proceeded at 25 °C within 48 h, 
and then the crude material was purified by semi-preparative HPLC to give CXCL14 
(4-Cys) 5 in 38% isolated yield. The purified CXCL14 (4-Cys) 5 (1.6 mg, 0.13 mol as 
5·25TFA) was oxidized with air in 3 M Gn·HCl-0.1 M sodium phosphate buffer (pH 7.7, 
concentration of the peptide: 0.05 mM) at 37 °C for 10 h. After oxidative folding 
followed by purification using semi-preparative HPLC, human CXCL14 6 (0.47 mg) 
was obtained in 39% isolated yield. 
 
Synthesis of dialdehyde linker 19
19
 
O,O’-Bis(3-aminopropyl)diethylene glycol 18 (100 mg, 0.45 mmol), 
4-folmylbenzoic acid 17 (545 mg, 3.6 mmol) and DMAP (44 mg, 0.36 mmol) were 
dissolved in CH2Cl2 (23 mL), and the obtained solution was cooled to 0 °C. The cold 
solution of DIPCI (562 L, 3.6 mmol) in CH2Cl2 (4.5 mL) was added dropwise over 10 
min to the reaction mixture. The obtained mixture was stirred at 0 °C for 4 h and then 
slowly warmed to room temperature. After 17 h, the reaction mixture was evaporated 
and then the residue was purified by silica gel column chromatography (eluting with 
CHCl3-MeOH mixture, 30: 1 (v/v)) to afford 185 mg (84%) of 19 as white powder. 
N-{13-[2-(4-Formylphenyl)acetamido]-4,7,10-trioxatridecyl}-4-formylbenzami
de 19; 
1
H-NMR (400 MHz, CDCl3)  1.87 (quint, J = 6.0 Hz, 4H), 3.54-3.63 (m, 
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16H), 7.38 (s, 2H), 7.92 (d, J = 8.4 Hz, 4H), 7.98 (d, J = 8.4 Hz, 4H), 10.06 (s, 2H); 
13
C-NMR (75 MHz, CDCl3)  28.7, 39.0, 70.0, 70.2, 70.5, 127.7, 129.6, 137.9, 139.8, 
166.1, 191.7; HRMS (ESI-TOF) m/z calcd for C26H33N2O7 ([M+H]
+
), 485.2288, found 
485.2278. 
 
Preparation of CXCL14 (50-77)-Lys(aminooxyacetyl)-NH2 20 
On NovaSyn TGR® resin (0.25 mmol amine/g) was coupled 
Fmoc-Lys(ivDde)-OH (3.0 equiv) in the presence of DIPCDI (3.0 equiv) and 
HOBt·H2O (3.3 equiv) in DMF at room temperature for 3 h. On the resulting resin, 
standard Fmoc SPPS mentioned above was performed for the chain elongation to give 
the protected peptide resin. Next, the resulting resin was treated with Boc2O (5.0 equiv) 
in DMF for protection of -amino group and then treated with 2% (v/v) 
hydrazine·H2O/DMF at room temperature for 4 days for ivDde removal. On the 
resulting resin was coupled Boc-aminooxyacetic acid (5.0 equiv) in the presence of 
DIPCDI (5.0 equiv) and HOBt·H2O (5.5 equiv) in DMF at room temperature for 3 h to 
afford the protected peptide resin. The resulting resin (200 mg) was treated with 
TFA-thioanisole-m-cresol-H2O-EDT (80:5:5:5:5, (v/v)) at room temperature for 1.5 h. 
After filtration of the resin, cooled Et2O was added to the filtrate, and the resulting 
precipitate was collected by centrifugation. The obtained precipitate was washed with 
cold Et2O and purified by preparative HPLC to give desired CXCL14 
(50-77)-Lys(aminooxyacetyl)-NH2 20 (9.4 mg, 13%). 
CXCL14 (50-77)-Lys(aminooxyacetyl)-NH2 20: Analytical HPLC condition, 
linear gradient of solvent B in solvent A, 5 to 60% over 30 min, retention time = 16.6 
min. Preparative HPLC condition: linear gradient of solvent B in solvent A, 18 to 28% 
over 30 min. MS (ESI-TOF) m/z calcd for [M + 4H]
4+
 956.5, found 956.5. 
 
Synthesis of Alexa Fluor® 488-conjugated CXCL14 derivative 26 using C–to–N 
directive sequential NCL and oxime ligation 
The First NCL: N-Thz peptide thioester 2 (2.7 mg, 1.0 mol) as middle Fr and 
N-Cys peptide 20 (3.9 mg, 1.0 mol) as C-terminal Fr were dissolved in 6 M 
Gn·HCl-0.1 M sodium phosphate buffer (pH 6.8) containing 0.5 mM EDTA and 1% 
(v/v) thiophenol to initiate the first NCL (concentration of each peptides: 1 mM). After 
completion of the reaction by incubation at 37 °C for 4 h, MeONH2·HCl was added 
directly to the ligation reaction mixture at a final concentration of 0.2 M. The opening 
of Thz ring to convert to Cys was completed within 2 h. The crude material was then 
purified by semi-preparative HPLC to afford ligated peptide 21 (3.2 mg, 50%). 
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The Second NCL: N-Terminal Fr 1 (1.8 mg, 0.51 mol) and the ligated product 
21 (3.2 mg, 0.51 mol) were dissolved at a final concentration of 1 mM in 6 M 
Gn·HCl-0.1 M sodium phosphate buffer (pH 6.8) containing 0.5 mM EDTA and 1% 
(v/v) thiophenol. After disappearance of the starting materials 1 and 21 by incubation of 
the reaction mixture at 37 °C for 6 h, the crude material was purified by 
semi-preparative HPLC to give CXCL14-K(aminooxyacetyl) (4-Cys) 22 (1.7 mg, 34%). 
Oxidation of the purified 22 (1.7 mg, 0.17 mol, concentration of the peptide: 0.050 
mM) with air was performed in 3 M Gn·HCl-0.1 M sodium phosphate buffer (pH 7.7). 
After incubation of the mixture at 37 °C for 20 h, CXCL14-K(aminooxyacetyl) 23 (0.85 
mg, 51%) was isolated by semi-preparative HPLC. 
Fluorescent dye conjugation: CXCL14-K(aminooxyacetyl) 23 (0.85 mg, 0.088 
mol) was incubated with excess amount of the linker 19 (10 equiv) in 6 M Gn·HCl-0.1 
M sodium phosphate buffer (pH 5.8) containing 0.5 mM EDTA at 37 ºC for 1 h to 
afford the linker conjugated CXCL14 derivative 24. After completion of the reaction, 
excess linker was washed out by extraction with CH2Cl2. Then Alexa Fluor® 488 
hydroxyamine 26 (4.0 equiv) in 6 M Gn·HCl-0.1 M sodium phosphate buffer (pH 4.0) 
containing 0.5 mM EDTA was added to the reaction mixture. After 7 h, 24 was 
disappeared and the crude material was purified by semi-preparative HPLC to give 
CXCL14-K(Alexa Fluor® 488) 26. 
 CXCL14 (29-77)-K(aminooxyacetyl) 21: Analytical HPLC condition: linear 
gradient of solvent B in solvent A, 5 to 45% over 30 min, retention time = 22.0 min. 
Semi-preparative HPLC condition: linear gradient of solvent B in solvent A, 19 to 29% 
over 30 min. MS (ESI-TOF) m/z calcd for [M + 6H]
6+
 1792.1, found 1791.9.
 
CXCL14-K(aminooxyacetyl) (4-Cys) 22: Analytical HPLC condition: linear 
gradient of solvent B in solvent A, 5 to 45% over 30 min, retention time = 21.9 min. 
Semi-preparative HPLC condition: linear gradient of solvent B in solvent A, 18 to 28% 
over 30 min. MS (ESI-TOF) m/z calcd for [M + 11H]
11+
 874.9, found 875.3. 
CXCL14-K(aminooxyacetyl) 23: Analytical HPLC condition: linear gradient 
of solvent B in solvent A, 5 to 45% over 30 min, retention time = 21.4 min. 
Semi-preparative HPLC condition: linear gradient of solvent B in solvent A, 18 to 28% 
over 30 min. MS (ESI-TOF) m/z calcd for [M + 7H]
7+
 1373.7, found 1373.7. 
Linker conjugated CXCL14 derivative 24: Analytical HPLC condition: linear 
gradient of solvent B in solvent A, 5 to 45% over 30 min, retention time = 22.8 min. MS 
(ESI-TOF) m/z calcd for [M + 6H]
6+
 1680.2, found 1680.0. 
CXCL14-K(Alexa Fluor® 488) 26: Analytical HPLC condition: linear gradient 
of solvent B in solvent A, 5 to 45% over 30 min, retention time = 22.7 min. 
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Semi-preparative HPLC condition: linear gradient of solvent B in solvent A, 18 to 28% 
over 30 min. MS (ESI-TOF) m/z calcd for [M + 6H]
6+
 1792.4, found 1791.9. 
 
Preparation of CXCL14 C-terminal fragment 27 possessing biotin on C-terminal 
additional lysine 
On NovaSyn® TGR resin (0.25 mmol amine/g) was coupled 
Fmoc-Lys(ivDde)-OH (3 equiv) in the presence of COMU
29
 (2.95 equiv) and DIPEA (6 
equiv) in DMF at room temperature for 2.5 h. On the resulting resin standard Fmoc 
SPPS mentioned above was performed for the chain elongation to give corresponding 
protected peptide-Lys(ivDde) resin. The resulting resin was treated with Boc2O (4.0 
equiv), HOBt (4.0 equiv) and DIPEA (4.0 equiv) in DMF to protect an N-terminal 
-amino group of elongated peptide. The resin was subsequently treated with 2% (v/v) 
hydrazine·H2O/DMF or 2% (v/v) hydrazine·H2O/NMP at room temperature for several 
times until the completion of removal of the ivDde group. The regenerating -amino 
group of the additional Lys residue was reacted with biotin (5.0 equiv) in the presence 
of DIPCDI (5.0 equiv) in DMF/DMSO = 1:1 (v/v) at room temperature overnight to 
afford protected peptide-K(biotin) resin. The completed resin (50 mg) was treated with 
TFA-thioanisole-m-cresol-H2O-EDT (80:5:5:5:5, (v/v)) at room temperature for 1.5 h. 
After filtration of the resin, cooded Et2O was added to the filtrate, and the resulting 
precipitate was collected by centrifugation. The obtained precipitate was washed with 
cold Et2O and purified by preparative HPLC to give desired biotin-labeled C-terminal 
fragment 27 (1.4 mg 6% as 27·9TFA). 
Biotinylated C-terminal Fr 27: Analytical HPLC condition, linear gradient of 
solvent B in solvent A, 5 to 45% over 30 min, retention time = 22.2 min. Preparative 
HPLC condition: linear gradient of solvent B in solvent A, 19 to 29% over 30 min. MS 
(ESI-TOF) m/z calcd for [M + 4H]
4+
 994.8, found 994.5. 
 
Synthesis of biotinylated CXCL14 29 using N–to–C-directive one-pot/sequential 
NCL with the use of the SEAlide peptide 
The first NCL between alkyl thioester peptide 1 (1.4 mg, 0.28 μmol as 
1·12TFA) and SEAlide peptide 2 (1.0 mg, 0.28 μmol as 2·6TFA) was performed in 6 M 
Gn·HCl-0.2 M HEPPS buffer containing 50 mM MPAA and 30 mM TCEP·HCl (pH 6.6, 
278 L, 1.0 mM each peptide) at 25 °C. The reaction was completed within 5 h. Then, 
peptide 27 (1.4 mg, 0.28 mg as 27·9TFA) in 1 M sodium phosphate buffer (pH 6.6, 278 
L) was added to the reaction mixture. The second NCL proceeded at 25 °C for 48 h, 
and then the crude material was purified by semi-preparative HPLC. The purified 
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CXCL14-K(biotin) (4-Cys) was folded by the same procedure as that employed for 
CXCL14 6 and the desired CXCL14-K(biotin) (672 g) was obtained in 25% isolated 
yield (2 steps). 
CXCL14-K(biotin) (4-Cys) 28: Analytical HPLC condition, linear gradient of 
solvent B in solvent A, 5 to 45% over 30 min, retention time = 21.8 min. 
Semi-preparative HPLC condition: linear gradient of solvent B in solvent A, 18 to 28% 
over 30 min. MS (ESI-TOF) m/z calcd for [M + 11H]
11+
 888.8, found 888.8. 
CXCL14-K(biotin) 29: Analytical HPLC condition, linear gradient of solvent B 
in solvent A, 5 to 45% over 30 min, retention time = 21.3 min. Preparative HPLC 
condition: linear gradient of solvent B in solvent A, 18 to 28% over 30 min. MS 
(ESI-TOF) m/z calcd for [M + 6H]
6+
 1628.0, found 1628.1. 
 
Chemotaxis assay 
Chemotaxis assays were conducted as previously described.
6
 Briefly, THP-1 
cells or BaF/3 cells were washed and resuspended at 10
6
 cells/mL in RPMI-1640 
medium containing 0.1% fatty acid-free BSA (Sigma) and 20 mM HEPES buffer (pH 
7.5; Invitrogen). Wells in a 24-well culture plate were filled with 550 L of 10 nM 
CXCL12. Chemotaxicell filter was placed in each well and the cells (200 L) were 
added to the upper chamber with or without 100nM synthetic CXCL14, recombinant 
CXCL14, or CXCL14-K(biotin). These plates were incubated at 37 °C for 2 h. The 
number of migrated cells in the lower chamber were determined using LSR 
Fortessa-X20 (BD Bioscience, San Jose, CA, USA) with 123 counting beads 
(Affymetrix Japan K.K., Tokyo, Japan) as a reference. 
 
Fluorescence activated cell sorting analysis 
HeLa cells were transfected with pCS2+GFP or pCS2+CXCR4-GFP 
expression vectors (CXCR4 corresponds to human CXCR 4 transcript variant 1: 
NM_001008540) by using polyethyleneimine MAX (Polyscience, Warrington, PA). 
Twenty four hours after transfection, cells were trypsinized, and incubated with 100 nM 
biotin (Wako), 100 nM CXCL14-K(biotin), or 100 nM CXCL14-K(biotin) plus 4M 
CXCL14 at 4 °C for 1 h. To determine the expression of human CXCR4, APC 
anti-human CD184 (CXCR4) antibody was used (clone 12G5: Biolegend). After 
incubation with APC-streptavidin (Life Technologies, Carlsbad, CA), cell surface 
binding of the biotinylated CXCL14 was measured by LSR Fortessa-X20. GFP positive 
cells were gated for the analyses of fluorescent intensity by FlowJo software (FlowJo, 
LLC, Ashland, OR). 
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Statistical analyses 
All statistical analyses were performed using ANOVA repeated measures 
analysis (Statview J5.0, Abacus Concepts). A p-value of <0.05 was considered 
significant for the unpaired Student’s t-test. 
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Chapter 2 
 
Preparation of H-Thz-CXCL14 (30-49, H49G)-OH 30 
Middle Fr 30 was prepared by hydrolysis of corresponding peptide thioester 31 
which was synthesized using the Boc SPPS in a manner similar to that employed for 
N-terminal Fr 1. Thioester 31 (1.9 mg, 0.73 mol) was incubated in 6 M Gn·HCl-0.1 M 
sodium phosphate buffer (pH 9.0) at 37 °C for 23 h (concentration of the peptide: 1.0 
mM). After completion of the hydrolysis, peptide 30 (0.50 mg, 28%) was obtained after 
HPLC purification. 
Middle Fr 30 (5.6 mg from 100 mg resin, 10%): Analytical HPLC condition, 
linear gradient of solvent B in solvent A, 5 to 45% over 30 min, retention time = 17.1 
min. Semi-preparative HPLC condition: linear gradient of solvent B in solvent A, 15 to 
40% over 30 min. MS (ESI-TOF) m/z calcd for [M + 3H]
3+
 809.4, found 809.3. 
Peptide thioester 31: Analytical HPLC condition, linear gradient of solvent B in 
solvent A, 5 to 45% over 30 min, retention time = 17.3 min. Preparative HPLC 
condition: linear gradient of solvent B in solvent A, 13 to 23% over 30 min. MS 
(ESI-TOF) m/z calcd for [M + 3H]
3+
 862.1, found 861.9. 
 
Preparation of H-Thz-CXCL14 (1-28)-CXCL14 (50-77) 32 
The (29-49) derivative 32 was generated as byproduct during the synthesis of 
other CXCL14 derivative using 33 as N-terminal Fr. Thioester 33 was prepared using 
the Boc SPPS in a manner similar to that employed for N-terminal Fr 1. During the 
synthesis of a CXCL14 derivative using N-terminal Fr 33, middle Fr 31, and C-terminal 
Fr 3 by conventional C–to–N-directive NCL method almost identical to that employed 
for CXCL14 6, HPLC purification afforded mixture of the first ligated product 
(conjugates of 31 and 3) and 3. The resulting mixture was subjected to the second NLC 
with N-terminal Fr 33. As a result, desired CXCL14 protein and the (29-49) derivative 
32 was isolated, respectively, after HPLC purification. 
H-Thz-CXCL14 (1-28)-CXCL14 (50-77) 32: Analytical HPLC condition, 
linear gradient of solvent B in solvent A, 5 to 45% over 30 min, retention time = 20.1 
min. Semi-preparative HPLC condition: linear gradient of solvent B in solvent A, 15 to 
35% over 30 min. MS (ESI-TOF) m/z calcd for [M + 5H]
5+
 1411.5, found 1410.9. 
H-Thz-CXCL14 (1-28)-SCH2CH2CO-Ala-NH2 33 (7.4 mg from 100 mg resin, 
16%): Analytical HPLC condition, linear gradient of solvent B in solvent A, 5 to 45% 
over 30 min, retention time = 15.5 min. Preparative HPLC condition: linear gradient of 
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solvent B in solvent A, 13 to 23% over 30 min. MS (ESI-TOF) m/z calcd for [M + 4H]
4+
 
902.7, found 902.5. 
 
Preparation of H-CXCL14 (1-49, H49G)-CXCL12 (50-72)-OH 34 
H-CXCL14 (1-49, H49G)-CXCL12 (50-72)-OH 34 was synthesized from 
N-terminal Fr 1, middle Fr 31, and CXCL12 (50-72) 35 as C-terminal Fr using 
conventional C–to–N-directive NCL method similar to that employed for CXCL14 6. 
The First NCL: N-Thz peptide thioester 31 (2.0 mg, 0.76 mol) as middle Fr 
and N-Cys peptide 35 (2.2 mg, 0.76 mol) as C-terminal Fr were dissolved in 6 M 
Gn·HCl-0.1 M sodium phosphate buffer (pH 6.8) containing 0.5 mM EDTA and 1% 
(v/v) thiophenol to initiate the first NCL (concentration of each peptides: 1.0 mM). After 
completion of the reaction by incubation at 37 °C for 3 h, MeONH2·HCl was added 
directly to the ligation reaction mixture at a final concentration of 0.2 M. The opening 
of Thz ring to convert to Cys was completed within 2 h. The crude material was purified 
by semi-preparative HPLC to afford ligated peptide (H-CXCL14 (29-49, 
H49G)-CXCL12 (50-72)-OH, 2.4 mg, 60%). 
The Second NCL: N-terminal Fr 1 (1.6 mg, 0.46 mol) and the resulting 
H-CXCL14 (29-49, H49G)-CXCL12 (50-72)-OH (2.4 mg, 0.46 mol) were dissolved 
in 6 M Gn·HCl-0.1 M sodium phosphate buffer (pH 6.8) containing 0.5 mM EDTA and 
1% (v/v) thiophenol (concentration of each peptides: 1.0 mM). After disappearance of 
the starting materials by incubation of the mixture at 37 °C for 4 h, the crude material 
was purified by semi-preparative HPLC to give reduced form H-CXCL14 (1-49, 
H49G)-CXCL12 (50-72)-OH (H-CXCL14 (1-49, H49G)-CXCL12 (50-72)-OH (4-Cys), 
2.2 mg, 55%). Oxidation of the resulting material (2.2 mg, 0.25 mol) with air was 
performed in 2.4 M Gn·HCl-0.1 M sodium phosphate buffer (pH 7.7, concentration of 
the peptide: 0.050 mM). After incubation of the mixture at 37 °C for 3 d, H-CXCL14 
(1-49, H49G)-CXCL12 (50-72)-OH 34 (0.47 mg, 22%) was isolated by 
semi-preparative HPLC. 
H-CXCL14 (1-49, H49G)-CXCL12 (50-72)-OH 34: Analytical HPLC 
condition, linear gradient of solvent B in solvent A, 5 to 45% over 30 min, retention 
time = 23.9 min. Semi-preparative HPLC condition: linear gradient of solvent B in 
solvent A, 20 to 45% over 30 min. MS (ESI-TOF) m/z calcd for [M + 9H]
9+
 956.6, 
found 957.2. 
CXCL12 (50-72) 35 (75 mg as 35·7TFA from 204 mg resin, 86%): Analytical 
HPLC condition, linear gradient of solvent B in solvent A, 5 to 65% over 30 min, 
retention time = 19.5 min. Preparative HPLC condition: linear gradient of solvent B in 
52 
 
solvent A, 13 to 27% over 37 min. MS (ESI-TOF) m/z calcd for [M + 4H]
4+
 724.4, 
found 724.4. 
H-CXCL14 (29-49, H49G)-CXCL12 (50-72)-OH: Analytical HPLC condition, 
linear gradient of solvent B in solvent A, 5 to 60% over 30 min, retention time = 19.8 
min. Preparative HPLC condition: linear gradient of solvent B in solvent A, 25 to 35% 
over 30 min. MS (ESI-TOF) m/z calcd for [M + 4H]
4+
 1323.2, found 1323.2. 
H-CXCL14 (1-49, H49G)-CXCL12 (50-72)-OH (4-Cys): Analytical HPLC 
condition, linear gradient of solvent B in solvent A, 5 to 60% over 30 min, retention 
time = 18.9 min. Semi-preparative HPLC condition: linear gradient of solvent B in 
solvent A, 26 to 36% over 30 min. MS (ESI-TOF) m/z calcd for [M + 10H]
10+
 861.5, 
found 861.5. 
 
Preparation of H- CXCL14 (51-77)-OH 36 
 H-CXCL14 (51-77)-OH 36 was synthesized using standard Fmoc SPPS in a 
fashion similar to that employed for C-terminal Fr 3. 
 CXCL14 (51-77) 36 (4.3 mg from 25 mg resin, 45%): Analytical HPLC 
condition, linear gradient of solvent B in solvent A, 5 to 60% over 30 min, retention 
time = 16.7 min. Preparative HPLC condition: linear gradient of solvent B in solvent A, 
20 to 30% over 30 min. MS (ESI-TOF) m/z calcd for [M + 3H]
3+
 1174.0, found 1173.7. 
 
Synthesis of the disulfide dimers of CXCL14 C-terminal fragments 
The requisite monomer peptides were prepared using standard Fmoc SPPS in a 
manner almost identical to that employed for C-terminal Fr 3. 
For synthesis of N2C 37, C-terminal Fr 3 (3.2 mg, 0.88 mol) was dissolved in 
0.1 M sodium phosphate buffer (pH 7.7, concentration of the peptide: 1.0 mM). After 
disappearance of the starting materials by incubation at 37 °C for 12 h, the crude 
material was purified by semi-preparative HPLC to give dimerized C-terminal Fr (N2C) 
37 (1.5 mg, 47%). Other mutant dimers were also synthesized using the method similar 
to that employed for N2C 37 with corresponding monomer peptides. 
 
N2C 37 from 3 
N2C 37: Analytical HPLC condition, linear gradient of solvent B in solvent A, 
5 to 45% over 30 min, retention time = 23.3 min. Semi-preparative HPLC condition: 
linear gradient of solvent B in solvent A, 19 to 29% over 30 min. MS (ESI-TOF) m/z 
calcd for [M + 5H]
5+
 1449.3, found 1449.7. 
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BF2C 38 from 39 
BF2C 38 (0.43 mg from 39 (2.0 mg, 0.55 mol), 22%): Analytical HPLC 
condition, linear gradient of solvent B in solvent A, 5 to 45% over 30 min, retention 
time = 20.5 min. Semi-preparative HPLC condition: linear gradient of solvent B in 
solvent A, 20 to 35% over 30 min. MS (ESI-TOF) m/z calcd for [M + 5H]
5+
 1462.5, 
found 1461.9. 
CXCL14 (50-77, b,f-EK) 39 (8.6 mg from 50 mg resin, 29%): Analytical 
HPLC condition, linear gradient of solvent B in solvent A, 5 to 65% over 30 min, 
retention time = 15.4 min. Preparative HPLC condition: linear gradient of solvent B in 
solvent A, 20 to 30% over 30 min. MS (ESI-TOF) m/z calcd for [M + 4H]
4+
 914.7, 
found 914.6. 
 
CG2C 40 from 41 
CG2C 40 (0.21 mg from 41 (1.1 mg, 0.30 mol), 19%): Analytical HPLC 
condition, linear gradient of solvent B in solvent A, 5 to 45% over 30 min, retention 
time = 22.3 min. Semi-preparative HPLC condition: linear gradient of solvent B in 
solvent A, 20 to 40% over 30 min. MS (ESI-TOF) m/z calcd for [M + 8H]
8+
 921.2, 
found 921.2. 
CXCL14 (50-77, c,g-EK) 41: Analytical HPLC condition, linear gradient of 
solvent B in solvent A, 5 to 65% over 30 min, retention time = 16.4 min. Preparative 
HPLC condition: linear gradient of solvent B in solvent A, 20 to 30% over 30 min. MS 
(ESI-TOF) m/z calcd for [M + 4H]
4+
 921.5, found 921.2. 
 
GD2C 44 from 45 
GD2C 44 (0.45 mg from 45 (2.0 mg, 0.55 mol), 23%): Analytical HPLC 
condition, linear gradient of solvent B in solvent A, 5 to 45% over 30 min, retention 
time = 19.8 min. Semi-preparative HPLC condition: linear gradient of solvent B in 
solvent A, 15 to 35% over 30 min. MS (ESI-TOF) m/z calcd for [M + 5H]
5+
 1455.0, 
found 1454.0. 
CXCL14 (50-77, g,d-EK) 45 (12 mg from 50 mg resin, 64%): Analytical 
HPLC condition, linear gradient of solvent B in solvent A, 5 to 45% over 30 min, 
retention time = 18.3 min. Preparative HPLC condition: linear gradient of solvent B in 
solvent A, 20 to 30% over 30 min. MS (ESI-TOF) m/z calcd for [M + 4H]
4+
 910.0, 
found 910.0. 
 
DA2C 46 from 47 
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 DA2C 46 (0.50 mg from 47 (1.3 mg, 0.36 mol), 40%): Analytical HPLC 
condition, linear gradient of solvent B in solvent A, 5 to 45% over 30 min, retention 
time = 16.4 min. Semi-preparative HPLC condition: linear gradient of solvent B in 
solvent A, 10 to 20% over 30 min. MS (ESI-TOF) m/z calcd for [M + 8H]
8+
 874.7, 
found 874.4. 
 CXCL14 (50-77, d,a-EK) 47 (5.9 mg from 50 mg resin, 29%): Analytical 
HPLC condition, linear gradient of solvent B in solvent A, 5 to 45% over 30 min, 
retention time = 15.3 min. Preparative HPLC condition: linear gradient of solvent B in 
solvent A, 12 to 18% over 30 min. MS (ESI-TOF) m/z calcd for [M + 4H]
4+
 875.0, 
found 874.7. 
 
AE2C 48 from 49 
 AE2C 48 (0.53 mg from 49 (1.1 mg, 0.32 mol), 48%): Analytical HPLC 
condition, linear gradient of solvent B in solvent A, 5 to 45% over 30 min, retention 
time = 16.2 min. Semi-preparative HPLC condition: linear gradient of solvent B in 
solvent A, 12 to 18% over 30 min. MS (ESI-TOF) m/z calcd for [M + 5H]
5+
 1397.7, 
found 1397.1. 
 CXCL14 (50-77, a,e-EK) 49 (9.3 mg from 50 mg resin, 45%): Analytical 
HPLC condition, linear gradient of solvent B in solvent A, 5 to 45% over 30 min, 
retention time = 15.1 min. Preparative HPLC condition: linear gradient of solvent B in 
solvent A, 10 to 19% over 30 min. MS (ESI-TOF) m/z calcd for [M + 4H]
4+
 874.2, 
found 874.0. 
 
EB2C 50 from 51 
 EB2C 50 (0.27 mg from 51 (0.85 mg, 0.23 mol), 31%): Analytical HPLC 
condition, linear gradient of solvent B in solvent A, 5 to 45% over 30 min, retention 
time = 19.4 min. Semi-preparative HPLC condition: linear gradient of solvent B in 
solvent A, 18 to 25% over 30 min. MS (ESI-TOF) m/z calcd for [M + 5H]
5+
 1459.7, 
found 1459.0. 
 CXCL14 (50-77, e,b-EK) 51 (6.1 mg from 50 mg resin, 36%): Analytical 
HPLC condition, linear gradient of solvent B in solvent A, 5 to 45% over 30 min, 
retention time = 18.9 min. Preparative HPLC condition: linear gradient of solvent B in 
solvent A, 18 to 25% over 30 min. MS (ESI-TOF) m/z calcd for [M + 4H]
4+
 913.0, 
found 912.7. 
 
Preparation of CXCL14 (50-77, f,c-EK) 43 
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The protected peptide resin was constructed on Wang resin (loading: 0.17 
mmol/g)
30
 using standard Fmoc SPPS mentioned above. The completed resin (25 mg) 
was treated with TFA-thioanisole-m-cresol-H2O-EDT (80:5:5:5:5, (v/v)) at room 
temperature for 1.5 h. After filtration of the resin, cooled Et2O was added to the filtrate 
and the resulting precipitate was collected by centrifugation. The obtained precipitate 
was washed with Et2O and purified by preparative HPLC to give desired CXCL14 
(50-77, f,c-EK) 43 (5.0 mg, 68%). 
CXCL14 (50-77, f,c-EK) 43: Analytical HPLC condition, linear gradient of 
solvent B in solvent A, 5 to 45% over 30 min, retention time = 21.5 min. Preparative 
HPLC condition: linear gradient of solvent B in solvent A, 20 to 30% over 30 min. MS 
(ESI-TOF) m/z calcd for [M + 4H]
4+
 903.2, found 903.0. 
 
Synthesis of FC2C 42 
FC2C 42 was synthesized from the corresponding monomer peptide 43 using 
the method similar to that employed for N2C 37. 
FC2C 42 (0.16 mg from 43 (1.9 mg, 0.53 mol), 8%): Analytical HPLC 
condition, linear gradient of solvent B in solvent A, 5 to 45% over 30 min, retention 
time = 22.8 min. Semi-preparative HPLC condition: linear gradient of solvent B in 
solvent A, 20 to 35% over 30 min. MS (ESI-TOF) m/z calcd for [M + 8H]
8+
 903.0, 
found 903.1. 
 
Preparation of aminooxyacety C-terminal fragment 52 and its c,g-EK mutant 54 
The protected peptide resin was constructed on Fmoc-Glu(O
t
Bu)-Alko-PEG 
resin (loading: 0.24 mmol amino acid/g) using standard Fmoc SPPS mentioned above. 
Coupling of Boc-aminooxyacetic acid (5.0 equiv) with -amino group on the resulting 
resin was subsequently subjected in the presence of DIPCDI (5.0 equiv) and HOBt·H2O 
(5.5 equiv) in DMF at room temperature for 5 h to afford protected aminooxyacetyl 
CXCL14 (51-77) peptide resin. The completed resin was treated with 
TFA-thioanisole-m-cresol-H2O-EDT (80:5:5:5:5, (v/v)) at room temperature for 1.5 h. 
After filtration of the resin, cooled Et2O was added to the filtrate and the resulting 
precipitate was collected by centrifugation. The obtained precipitate was washed with 
Et2O and purified by preparative HPLC to give peptide 52 or 54, respectively. 
Aminooxyacetylated CXCL14 (51-77) 52 (9.9 mg from 50 mg resin, 51%): 
Analytical HPLC condition, linear gradient of solvent B in solvent A, 5 to 45% over 30 
min, retention time = 21.9 min. Preparative HPLC condition: linear gradient of solvent 
B in solvent A, 19 to 29% over 30 min. MS (ESI-TOF) m/z calcd for [M + 4H]
4+
 899.0, 
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found 898.7. 
Aminooxyacetylated CXCL14 (51-77, c,g-EK) 54 (68 mg from 394 mg resin, 
39%): Analytical HPLC condition, linear gradient of solvent B in solvent A, 5 to 45% 
over 30 min, retention time = 21.2 min. Preparative HPLC condition: linear gradient of 
solvent B in solvent A, 18 to 28% over 30 min. MS (ESI-TOF) m/z calcd for [M + 4H]
4+
 
914.0, found 913.6. 
 
Synthesis of the oxime dimers of CXCL14 C-terminal fragments 
Linker 19 was added to the solution of excess amount of peptide 52 or 54 in 6 
M Gn·HCl-0.1 M sodium phosphate buffer (pH 7.6, concentration of the linker 19: 0.30 
mM) containing 0.05 mM EDTA. After incubation at 37 °C for 3 h, the reaction mixture 
was purified by semi-preparative HPLC to give dimer peptide 53 or 55, respectively. 
N2O 53 (1.6 mg from linker 19 (0.12 mg, 0.25 mol), 85%): Analytical HPLC 
condition, linear gradient of solvent B in solvent A, 5 to 45% over 30 min, retention 
time = 24.8 min. Semi-preparative HPLC condition: linear gradient of solvent B in 
solvent A, 20 to 35% over 30 min. MS (ESI-TOF) m/z calcd for [M + 8H]
8+
 955.0, 
found 954.8. 
 CG2O 55 (13 mg from linker 19 (0.70 mg, 1.4 mol), 92%): Analytical HPLC 
condition, linear gradient of solvent B in solvent A, 5 to 45% over 30 min, retention 
time = 23.6 min. Preparative HPLC condition: linear gradient of solvent B in solvent A, 
20 to 35% over 30 min. MS (ESI-TOF) m/z calcd for [M + 8H]
8+
 970.0, found 969.8. 
 
Preparation of the monomer peptide with c,g-EK mutation 56 
The monomer peptide with c,g-EK mutation 56 was synthesized using standard 
Fmoc SPPS in a manner similar to that employed for C-terminal Fr 3. 
 CXCL14 (51-77, c,g-EK) 56 (3.3 mg from 25 mg resin, 31%): Analytical 
HPLC condition, linear gradient of solvent B in solvent A, 5 to 65% over 30 min, 
retention time = 15.7 min. Preparative HPLC condition: linear gradient of solvent B in 
solvent A, 20 to 30% over 30 min. MS (ESI-TOF) m/z calcd for [M + 4H]
4+
 895.7, 
found 895.5. 
 
Synthesis of the trimer of CXCL14-C-terminal fragment 57 
Commercially available trialdehyde linker 58 (0.037 mg, 0.23 mol) was added 
to the solution of excess amount of peptide 52 in 6 M Gn·HCl-0.1 M sodium phosphate 
buffer (pH 5.5, concentration of the linker 58: 0.33 mM) containing 0.05 mM EDTA. 
After incubation at 37 °C for 4 h, the reaction mixture was purified by semi-preparative 
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HPLC to give trimerized peptide 57 (0.20 mg, 8%). 
Trimer peptide 57: Analytical HPLC condition, linear gradient of solvent B in 
solvent A, 5 to 45% over 30 min, retention time = 24.5 min. Preparative HPLC 
condition: linear gradient of solvent B in solvent A, 23 to 31% over 30 min. MS 
(ESI-TOF) m/z calcd for [M + 9H]
9+
 1210.3, found 1210.6. 
 
Synthesis of the disulfide dimers with mutation of an aromatic amino acid residue 
to alanine 
 These monomeric mutants were prepared using standard Fmoc SPPS in a 
manner almost identical to that employed for C-terminal Fr 3. The mutant dimers were 
synthesized using the method similar to that employed for N2C 37 with corresponding 
monomer peptides. 
 
The dimer of CXCL14 (50-77, W64A) 59 from 60 
 Dimer of CXCL14 (50-77, W64A) 59 (0.64 mg from 60 (1.9 mg, 0.55 mol), 
33%): Analytical HPLC condition, linear gradient of solvent B in solvent A, 5 to 45% 
over 30 min, retention time = 21.7 min. Semi-preparative HPLC condition: linear 
gradient of solvent B in solvent A, 19 to 29% over 30 min. MS (ESI-TOF) m/z calcd for 
[M + 6H]
6+
 1169.6, found 1169.6. 
 CXCL14 (50-77, W64A) 60 (7.4 mg from 100 mg resin, 17%): Analytical 
HPLC condition, linear gradient of solvent B in solvent A, 5 to 45% over 30 min, 
retention time = 21.0 min. Preparative HPLC condition: linear gradient of solvent B in 
solvent A, 17 to 27% over 30 min. MS (ESI-TOF) m/z calcd for [M + 4H]
4+
 877.7, 
found 877.4. 
 
The dimer of CXCL14 (50-77, Y65A) 61 from 62 
 Dimer of CXCL14 (50-77, Y65A) 61 (0.73 mg from 62 (1.9 mg, 0.53 mol), 
39%): Analytical HPLC condition, linear gradient of solvent B in solvent A, 5 to 45% 
over 30 min, retention time = 22.9 min. Semi-preparative HPLC condition: linear 
gradient of solvent B in solvent A, 20 to 30% over 30 min. MS (ESI-TOF) m/z calcd for 
[M + 6H]
6+
 1177.3, found 1177.4. 
 CXCL14 (50-77, Y65A) 62 (7.9 mg from 100 mg resin, 18%): Analytical 
HPLC condition, linear gradient of solvent B in solvent A, 5 to 45% over 30 min, 
retention time = 21.9 min. Preparative HPLC condition: linear gradient of solvent B in 
solvent A, 18 to 28% over 30 min. MS (ESI-TOF) m/z calcd for [M + 4H]
4+
 883.5, 
found 883.1. 
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The dimer of CXCL14 (50-77, W68A) 63 from 64 
Dimer of CXCL14 (50-77, W68A) 63 (0.78 mg from 64 (2.0 mg, 0.57 mol), 
39%): Analytical HPLC condition, linear gradient of solvent B in solvent A, 5 to 45% 
over 30 min, retention time = 21.4 min. Semi-preparative HPLC condition: linear 
gradient of solvent B in solvent A, 19 to 29% over 30 min. MS (ESI-TOF) m/z calcd for 
[M + 5H]
5+
 1403.3, found 1403.3. 
 CXCL14 (50-77, W68A) 64 (11 mg from 100 mg resin, 26%): Analytical 
HPLC condition, linear gradient of solvent B in solvent A, 5 to 45% over 30 min, 
retention time = 20.3 min. Preparative HPLC condition: linear gradient of solvent B in 
solvent A, 17 to 27% over 30 min. MS (ESI-TOF) m/z calcd for [M + 4H]
4+
 877.7, 
found 877.4. 
 
The dimer of CXCL14 (50-77, Y75A) 65 from 66 
 Dimer of CXCL14 (50-77, Y75A) 65 (1.1 mg from 66 (2.3 mg, 0.66 mol), 
46%): Analytical HPLC condition, linear gradient of solvent B in solvent A, 5 to 45% 
over 30 min, retention time = 23.1 min. Semi-preparative HPLC condition: linear 
gradient of solvent B in solvent A, 20 to 30% over 30 min. MS (ESI-TOF) m/z calcd for 
[M + 5H]
5+
 1412.5, found 1412.4. 
 CXCL14 (50-77, Y75A) 66 (11 mg from 100 mg resin, 25%): Analytical HPLC 
condition, linear gradient of solvent B in solvent A, 5 to 45% over 30 min, retention 
time = 21.8 min. Preparative HPLC condition: linear gradient of solvent B in solvent A, 
18 to 28% over 30 min. MS (ESI-TOF) m/z calcd for [M + 4H]
4+
 883.5, found 883.4. 
 
Synthesis of the disulfide dimers of CXCL14 C-terminal fragments with deletion 
from C-terminus 
The requisite monomers were prepared using standard Fmoc SPPS in a fashion 
almost identical to that employed for C-terminal Fr 3 (68 and 80) or CXCL14 (50-77, 
f,c-EK) 43 (70, 72, 74, 76, 78, 82, 84, 86, 88, 90, and 92), respectively. The deleted 
dimers were synthesized using the method similar to that employed for N2C 37 with 
corresponding monomer peptides. 
 
The dimer of CXCL14 (50-76) 67 from 68 
Dimer of CXCL14 (50-76) 67 (1.5 mg from 68 (2.3 mg, 0.66 mol), 66%): 
Analytical HPLC condition, linear gradient of solvent B in solvent A, 5 to 45% over 30 
min, retention time = 22.3 min. Semi-preparative HPLC condition: linear gradient of 
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solvent B in solvent A, 20 to 40% over 30 min. MS (ESI-TOF) m/z calcd for [M + 5H]
5+
 
1397.7, found 1397.3. 
 CXCL14 (50-76) 68 (13 mg from 50 mg resin, 62%): Analytical HPLC 
condition, linear gradient of solvent B in solvent A, 5 to 45% over 30 min, retention 
time = 21.2 min. Preparative HPLC condition: linear gradient of solvent B in solvent A, 
20 to 30% over 30 min. MS (ESI-TOF) m/z calcd for [M + 4H]
4+
 874.2, found 874.0. 
 
The dimer of CXCL14 (50-75) 69 from 70 
Dimer of CXCL14 (50-75) 69 (1.1 mg from 70 (2.1 mg, 0.61 mol), 55%): 
Analytical HPLC condition, linear gradient of solvent B in solvent A, 5 to 45% over 30 
min, retention time = 22.3 min. Semi-preparative HPLC condition: linear gradient of 
solvent B in solvent A, 20 to 35% over 30 min. MS (ESI-TOF) m/z calcd for [M + 5H]
5+
 
1346.1, found 1346.2. 
 CXCL14 (50-75) 70 (7.8 mg from 50 mg resin, 36%): Analytical HPLC 
condition, linear gradient of solvent B in solvent A, 5 to 45% over 30 min, retention 
time = 21.1 min. Preparative HPLC condition: linear gradient of solvent B in solvent A, 
20 to 30% over 30 min. MS (ESI-TOF) m/z calcd for [M + 4H]
4+
 842.0, found 841.8. 
 
The dimer of CXCL14 (50-74) 71 from 72 
 Dimer of CXCL14 (50-74) 71 (0.90 mg from 72 (2.0 mg, 0.63 mol), 45%): 
Analytical HPLC condition, linear gradient of solvent B in solvent A, 5 to 45% over 30 
min, retention time = 21.7 min. Semi-preparative HPLC condition: linear gradient of 
solvent B in solvent A, 20 to 35% over 30 min. MS (ESI-TOF) m/z calcd for [M + 5H]
5+
 
1280.9, found 1280.5. 
 CXCL14 (50-74) 72 (5.2 mg from 50 mg resin, 33%): Analytical HPLC 
condition, linear gradient of solvent B in solvent A, 5 to 45% over 30 min, retention 
time = 20.3 min. Preparative HPLC condition: linear gradient of solvent B in solvent A, 
15 to 25% over 30 min. MS (ESI-TOF) m/z calcd for [M + 4H]
4+
 801.2, found 801.0. 
 
The dimer of CXCL14 (50-73) 73 from 74 
 Dimer of CXCL14 (50-73) 73 (0.82 mg from 74 (1.8 mg, 0.58 mol), 45%): 
Analytical HPLC condition, linear gradient of solvent B in solvent A, 5 to 45% over 30 
min, retention time = 21.5 min. Semi-preparative HPLC condition: linear gradient of 
solvent B in solvent A, 20 to 35% over 30 min. MS (ESI-TOF) m/z calcd for [M + 7H]
7+
 
886.9, found 887.2. 
 CXCL14 (50-73) 74 (4.5 mg from 50 mg resin, 20%): Analytical HPLC 
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condition, linear gradient of solvent B in solvent A, 5 to 45% over 30 min, retention 
time = 20.3 min. Preparative HPLC condition: linear gradient of solvent B in solvent A, 
20 to 30% over 30 min. MS (ESI-TOF) m/z calcd for [M + 3H]
3+
 1034.9, found 1034.4. 
 
The dimer of CXCL14 (50-72) 75 from 76 
 Dimer of CXCL14 (50-72) 75 (1.0 mg from 76 (2.1 mg, 0.71 mol), 49%): 
Analytical HPLC condition, linear gradient of solvent B in solvent A, 5 to 45% over 30 
min, retention time = 21.6 min. Semi-preparative HPLC condition: linear gradient of 
solvent B in solvent A, 20 to 35% over 30 min. MS (ESI-TOF) m/z calcd for [M + 5H]
5+
 
1178.8, found 1178.5. 
 CXCL14 (50-72) 76 (11 mg from 50 mg resin, 65%): Analytical HPLC 
condition, linear gradient of solvent B in solvent A, 5 to 45% over 30 min, retention 
time = 20.1 min. Preparative HPLC condition: linear gradient of solvent B in solvent A, 
18 to 28% over 30 min. MS (ESI-TOF) m/z calcd for [M + 4H]
4+
 737.4, found 737.5. 
 
The dimer of CXCL14 (50-71) 77 from 78 
 Dimer of CXCL14 (50-71) 77 (1.3 mg from 78 (2.7 mg, 0.95 mol), 48%): 
Analytical HPLC condition, linear gradient of solvent B in solvent A, 5 to 45% over 30 
min, retention time = 21.8 min. Semi-preparative HPLC condition: linear gradient of 
solvent B in solvent A, 20 to 35% over 30 min. MS (ESI-TOF) m/z calcd for [M + 5H]
5+
 
1116.4, found 1116.3. 
 CXCL14 (50-71) 78: Analytical HPLC condition, linear gradient of solvent B 
in solvent A, 5 to 45% over 30 min, retention time = 20.3 min. Preparative HPLC 
condition: linear gradient of solvent B in solvent A, 19 to 29% over 30 min. MS 
(ESI-TOF) m/z calcd for [M + 3H]
3+
 930.8, found 930.6. 
 
The dimer of CXCL14 (50-70) 79 from 80 
 Dimer of CXCL14 (50-70) 79 (0.95 mg from 80 (1.9 mg, 0.71 mol), 51%): 
Analytical HPLC condition, linear gradient of solvent B in solvent A, 5 to 45% over 30 
min, retention time = 22.4 min. Semi-preparative HPLC condition: linear gradient of 
solvent B in solvent A, 20 to 35% over 30 min. MS (ESI-TOF) m/z calcd for [M + 4H]
4+
 
1331.2, found 1330.9. 
 CXCL14 (50-70) 80 (9.5 mg from 50 mg resin, 52%): Analytical HPLC 
condition, linear gradient of solvent B in solvent A, 5 to 45% over 30 min, retention 
time = 20.9 min. Preparative HPLC condition: linear gradient of solvent B in solvent A, 
19 to 29% over 30 min. MS (ESI-TOF) m/z calcd for [M + 3H]
3+
 888.1, found 887.8. 
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The dimer of CXCL14 (50-69) 81 from 82 
 Dimer of CXCL14 (50-69) 81 (1.5 mg from 82 (2.8 mg, 1.1 mol), 52%): 
Analytical HPLC condition, linear gradient of solvent B in solvent A, 5 to 45% over 30 
min, retention time = 22.6 min. Semi-preparative HPLC condition: linear gradient of 
solvent B in solvent A, 20 to 35% over 30 min. MS (ESI-TOF) m/z calcd for [M + 5H]
5+
 
1013.5, found 1013.7. 
 CXCL14 (50-69) 82: Analytical HPLC condition, linear gradient of solvent B 
in solvent A, 5 to 45% over 30 min, retention time = 20.8 min. Preparative HPLC 
condition: linear gradient of solvent B in solvent A, 19 to 29% over 30 min. MS 
(ESI-TOF) m/z calcd for [M + 3H]
3+
 845.1, found 844.9. 
 
The dimer of CXCL14 (50-68) 83 from 84 
 Dimer of CXCL14 (50-68) 83 (0.89 mg from 84 (1.9 mg, 0.77 mol), 48%): 
Analytical HPLC condition, linear gradient of solvent B in solvent A, 5 to 45% over 30 
min, retention time = 23.5 min. Semi-preparative HPLC condition: linear gradient of 
solvent B in solvent A, 20 to 35% over 30 min. MS (ESI-TOF) m/z calcd for [M + 4H]
4+
 
1209.6, found 1209.4. 
 CXCL14 (50-68) 84 (1.9 mg from 50 mg resin, 10%): Analytical HPLC 
condition, linear gradient of solvent B in solvent A, 5 to 45% over 30 min, retention 
time = 21.8 min. Preparative HPLC condition: linear gradient of solvent B in solvent A, 
20 to 30% over 30 min. MS (ESI-TOF) m/z calcd for [M + 3H]
3+
 807.1, found 806.9. 
 
The dimer of CXCL14 (50-67) 85 from 86 
 Dimer of CXCL14 (50-67) 85 (1.5 mg from 86 (2.8 mg, 1.2 mol), 53%): 
Analytical HPLC condition, linear gradient of solvent B in solvent A, 5 to 45% over 30 
min, retention time = 20.5 min. Semi-preparative HPLC condition: linear gradient of 
solvent B in solvent A, 20 to 35% over 30 min. MS (ESI-TOF) m/z calcd for [M + 4H]
4+
 
1116.6, found 1116.2. 
 CXCL14 (50-67) 86: Analytical HPLC condition, linear gradient of solvent B 
in solvent A, 5 to 45% over 30 min, retention time = 19.0 min. Preparative HPLC 
condition: linear gradient of solvent B in solvent A, 17 to 27% over 30 min. MS 
(ESI-TOF) m/z calcd for [M + 3H]
3+
 745.1, found 745.0. 
 
The dimer of CXCL14 (50-66) 87 from 88 
 Dimer of CXCL14 (50-66) 87 (0.90 mg from 88 (1.9 mg, 0.89 mol), 47%): 
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Analytical HPLC condition, linear gradient of solvent B in solvent A, 5 to 45% over 30 
min, retention time = 20.0 min. Semi-preparative HPLC condition: linear gradient of 
solvent B in solvent A, 20 to 30% over 30 min. MS (ESI-TOF) m/z calcd for [M + 4H]
4+
 
1081.1, found 1080.8. 
 CXCL14 (50-66) 88 (11 mg from 50 mg resin, 48%): Analytical HPLC 
condition, linear gradient of solvent B in solvent A, 5 to 45% over 30 min, retention 
time = 18.5 min. Preparative HPLC condition: linear gradient of solvent B in solvent A, 
16 to 26% over 30 min. MS (ESI-TOF) m/z calcd for [M + 3H]
3+
 721.4, found 721.3. 
 
The dimer of CXCL14 (50-65) 89 from 90 
 Dimer of CXCL14 (50-65) 89 (1.0 mg from 90 (2.7 mg, 1.3 mol), 39%): 
Analytical HPLC condition, linear gradient of solvent B in solvent A, 5 to 45% over 30 
min, retention time = 21.6 min. Semi-preparative HPLC condition: linear gradient of 
solvent B in solvent A, 20 to 35% over 30 min. MS (ESI-TOF) m/z calcd for [M + 4H]
4+
 
1024.1, found 1023.7. 
 CXCL14 (50-65) 90: Analytical HPLC condition, linear gradient of solvent B 
in solvent A, 5 to 45% over 30 min, retention time = 19.8 min. Preparative HPLC 
condition: linear gradient of solvent B in solvent A, 17 to 27% over 30 min. MS 
(ESI-TOF) m/z calcd for [M + 3H]
3+
 683.4, found 683.3. 
 
The dimer of CXCL14 (50-64) 91 from 92 
 Dimer of CXCL14 (50-64) 91 (0.82 mg from 92 (1.8 mg, 0.96 mol), 46%): 
Analytical HPLC condition, linear gradient of solvent B in solvent A, 5 to 45% over 30 
min, retention time = 20.6 min. Semi-preparative HPLC condition: linear gradient of 
solvent B in solvent A, 20 to 30% over 30 min. MS (ESI-TOF) m/z calcd for [M + 4H]
4+
 
942.5, found 942.3. 
 CXCL14 (50-64) 92 (12 mg from 50 mg resin, 54%): Analytical HPLC 
condition, linear gradient of solvent B in solvent A, 5 to 45% over 30 min, retention 
time = 18.9 min. Preparative HPLC condition: linear gradient of solvent B in solvent A, 
15 to 25% over 30 min. MS (ESI-TOF) m/z calcd for [M + 3H]
3+
 629.0, found 629.0. 
 
Synthesis of the disulfide dimers of CXCL14 C-terminal fragments with deletion 
from N-terminus 
The requisite monomers were prepared using standard Fmoc SPPS in a manner 
almost identical to that employed for C-terminal Fr 3. The deleted dimers were 
synthesized using the method similar to that employed for N2C 37 with corresponding 
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monomer peptides. 
 
The dimer of CXCL14 (52-77) 93 from 94 
 Dimer of CXCL14 (52-77) 93 (0.66 mg from 94 (1.4 mg, 0.39 mol), 48%): 
Analytical HPLC condition, linear gradient of solvent B in solvent A, 5 to 45% over 30 
min, retention time = 22.7 min. Semi-preparative HPLC condition: linear gradient of 
solvent B in solvent A, 21 to 31% over 30 min. MS (ESI-TOF) m/z calcd for [M + 5H]
5+
 
1404.1, found 1403.4. 
 CXCL14 (52-77) 94: Analytical HPLC condition, linear gradient of solvent B 
in solvent A, 5 to 45% over 30 min, retention time = 21.5 min. Preparative HPLC 
condition: linear gradient of solvent B in solvent A, 20 to 30% over 30 min. MS 
(ESI-TOF) m/z calcd for [M + 4H]
4+
 878.2, found 878.0. 
 
The dimer of CXCL14 (53-77) 95 from 96 
 Dimer of CXCL14 (53-77) 95 (0.64 mg from 96 (1.2 mg, 0.34 mol), 56%): 
Analytical HPLC condition, linear gradient of solvent B in solvent A, 5 to 45% over 30 
min, retention time = 23.1 min. Semi-preparative HPLC condition: linear gradient of 
solvent B in solvent A, 21 to 31% over 30 min. MS (ESI-TOF) m/z calcd for [M + 5H]
5+
 
1349.3, found 1348.7. 
 CXCL14 (53-77) 96: Analytical HPLC condition, linear gradient of solvent B 
in solvent A, 5 to 45% over 30 min, retention time = 22.0 min. Preparative HPLC 
condition: linear gradient of solvent B in solvent A, 19 to 29% over 30 min. MS 
(ESI-TOF) m/z calcd for [M + 3H]
3+
 1124.9, found 1124.5. 
 
The dimer of CXCL14 (54-77) 97 from 98 
 Dimer of CXCL14 (54-77) 97 (0.72 mg from 98 (1.4 mg, 0.44 mol), 51%): 
Analytical HPLC condition, linear gradient of solvent B in solvent A, 5 to 45% over 30 
min, retention time = 22.5 min. Semi-preparative HPLC condition: linear gradient of 
solvent B in solvent A, 21 to 31% over 30 min. MS (ESI-TOF) m/z calcd for [M + 5H]
5+
 
1310.5, found 1310.0. 
 CXCL14 (54-77) 98: Analytical HPLC condition, linear gradient of solvent B 
in solvent A, 5 to 45% over 30 min, retention time = 21.9 min. Preparative HPLC 
condition: linear gradient of solvent B in solvent A, 19 to 29% over 30 min. MS 
(ESI-TOF) m/z calcd for [M + 3H]
3+
 1092.6, found 1092.2. 
 
The dimer of CXCL14 (55-77) 99 from 100 
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 Dimer of CXCL14 (55-77) 99 (0.75 mg from 100 (1.6 mg, 0.50 mol), 47%): 
Analytical HPLC condition, linear gradient of solvent B in solvent A, 5 to 45% over 30 
min, retention time = 23.5 min. Semi-preparative HPLC condition: linear gradient of 
solvent B in solvent A, 21 to 31% over 30 min. MS (ESI-TOF) m/z calcd for [M + 5H]
5+
 
1259.2, found 1258.7. 
 CXCL14 (55-77) 100: Analytical HPLC condition, linear gradient of solvent B 
in solvent A, 5 to 45% over 30 min, retention time = 22.8 min. Preparative HPLC 
condition: linear gradient of solvent B in solvent A, 20 to 30% over 30 min. MS 
(ESI-TOF) m/z calcd for [M + 3H]
3+
 1049.9, found 1049.6. 
 
The dimer of CXCL14 (56-77) 101 from 102 
 Dimer of CXCL14 (56-77) 101 (0.40 mg from 102 (1.1 mg, 0.35 mol), 38%): 
Analytical HPLC condition, linear gradient of solvent B in solvent A, 5 to 45% over 30 
min, retention time = 22.4 min. Semi-preparative HPLC condition: linear gradient of 
solvent B in solvent A, 21 to 31% over 30 min. MS (ESI-TOF) m/z calcd for [M + 5H]
5+
 
1214.0, found 1213.7. 
 CXCL14 (56-77) 102: Analytical HPLC condition, linear gradient of solvent B 
in solvent A, 5 to 45% over 30 min, retention time = 21.6 min. Preparative HPLC 
condition: linear gradient of solvent B in solvent A, 18 to 28% over 30 min. MS 
(ESI-TOF) m/z calcd for [M + 3H]
3+
 1012.2, found 1011.9. 
 
The dimer of CXCL14 (57-77) 103 from 104 
 Dimer of CXCL14 (57-77) 103 (0.53 mg from 104 (0.84 mg, 0.29 mol), 
63%): Analytical HPLC condition, linear gradient of solvent B in solvent A, 5 to 45% 
over 30 min, retention time = 22.5 min. Semi-preparative HPLC condition: linear 
gradient of solvent B in solvent A, 20 to 30% over 30 min. MS (ESI-TOF) m/z calcd for 
[M + 5H]
5+
 1162.8, found 1162.3. 
 CXCL14 (57-77) 104: Analytical HPLC condition, linear gradient of solvent B 
in solvent A, 5 to 45% over 30 min, retention time = 21.7 min. Preparative HPLC 
condition: linear gradient of solvent B in solvent A, 18 to 28% over 30 min. MS 
(ESI-TOF) m/z calcd for [M + 3H]
3+
 969.5, found 969.2. 
 
The dimer of CXCL14 (58-77) 105 from 106 
 Dimer of CXCL14 (58-77) 105 (0.41 mg from 106 (1.1 mg, 0.38 mol), 38%): 
Analytical HPLC condition, linear gradient of solvent B in solvent A, 5 to 45% over 30 
min, retention time = 22.3 min. Semi-preparative HPLC condition: linear gradient of 
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solvent B in solvent A, 20 to 30% over 30 min. MS (ESI-TOF) m/z calcd for [M + 4H]
4+
 
1409.7, found 1409.3. 
 CXCL14 (58-77) 106: Analytical HPLC condition, linear gradient of solvent B 
in solvent A, 5 to 45% over 30 min, retention time = 21.2 min. Preparative HPLC 
condition: linear gradient of solvent B in solvent A, 19 to 29% over 30 min. MS 
(ESI-TOF) m/z calcd for [M + 3H]
3+
 940.5, found 940.2. 
 
The dimer of CXCL14 (59-77) 107 from 108 
 Dimer of CXCL14 (59-77) 107 (0.54 mg from 108 (1.2 mg, 0.43 mol), 45%): 
Analytical HPLC condition, linear gradient of solvent B in solvent A, 5 to 45% over 30 
min, retention time = 22.2 min. Semi-preparative HPLC condition: linear gradient of 
solvent B in solvent A, 20 to 30% over 30 min. MS (ESI-TOF) m/z calcd for [M + 4H]
4+
 
1359.2, found 1358.6. 
 CXCL14 (59-77) 108: Analytical HPLC condition, linear gradient of solvent B 
in solvent A, 5 to 45% over 30 min, retention time = 21.0 min. Preparative HPLC 
condition: linear gradient of solvent B in solvent A, 19 to 29% over 30 min. MS 
(ESI-TOF) m/z calcd for [M + 3H]
3+
 906.8, found 906.4. 
 
The dimer of CXCL14 (60-77) 109 from 110 
 Dimer of CXCL14 (60-77) 109 (0.33 mg from 110 (1.2 mg, 0.47 mol), 27%): 
Analytical HPLC condition, linear gradient of solvent B in solvent A, 5 to 45% over 30 
min, retention time = 22.8 min. Semi-preparative HPLC condition: linear gradient of 
solvent B in solvent A, 20 to 30% over 30 min. MS (ESI-TOF) m/z calcd for [M + 4H]
4+
 
1295.1, found 1294.7. 
 CXCL14 (60-77) 110: Analytical HPLC condition, linear gradient of solvent B 
in solvent A, 5 to 45% over 30 min, retention time = 22.3 min. Preparative HPLC 
condition: linear gradient of solvent B in solvent A, 19 to 29% over 30 min. MS 
(ESI-TOF) m/z calcd for [M + 3H]
3+
 864.1, found 863.8. 
 
The dimer of CXCL14 (61-77) 111 from 112 
 Dimer of CXCL14 (61-77) 111 (0.27 mg from 112 (1.2 mg, 0.47 mol), 23%): 
Analytical HPLC condition, linear gradient of solvent B in solvent A, 5 to 45% over 30 
min, retention time = 23.8 min. Semi-preparative HPLC condition: linear gradient of 
solvent B in solvent A, 20 to 30% over 30 min. MS (ESI-TOF) m/z calcd for [M + 4H]
4+
 
1217.1, found 1216.8. 
 CXCL14 (61-77) 112: Analytical HPLC condition, linear gradient of solvent B 
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in solvent A, 5 to 45% over 30 min, retention time = 22.9 min. Preparative HPLC 
condition: linear gradient of solvent B in solvent A, 18 to 28% over 30 min. MS 
(ESI-TOF) m/z calcd for [M + 3H]
3+
 812.1, found 811.9. 
 
The dimer of CXCL14 (62-77) 113 from 114 
 Dimer of CXCL14 (62-77) 113 (0.60 mg from 114 (1.1 mg, 0.46 mol), 56%): 
Analytical HPLC condition, linear gradient of solvent B in solvent A, 5 to 45% over 30 
min, retention time = 22.2 min. Semi-preparative HPLC condition: linear gradient of 
solvent B in solvent A, 18 to 28% over 30 min. MS (ESI-TOF) m/z calcd for [M + 4H]
4+
 
1143.5, found 1143.1. 
 CXCL14 (62-77) 114: Analytical HPLC condition, linear gradient of solvent B 
in solvent A, 5 to 45% over 30 min, retention time = 20.8 min. Preparative HPLC 
condition: linear gradient of solvent B in solvent A, 18 to 28% over 30 min. MS 
(ESI-TOF) m/z calcd for [M + 3H]
3+
 763.0, found 763.0. 
 
The dimer of CXCL14 (63-77) 115 from 116 
 Dimer of CXCL14 (63-77) 115 (0.39 mg from 116 (1.1 mg, 0.50 mol), 36%): 
Analytical HPLC condition, linear gradient of solvent B in solvent A, 5 to 45% over 30 
min, retention time = 20.2 min. Semi-preparative HPLC condition: linear gradient of 
solvent B in solvent A, 18 to 28% over 30 min. MS (ESI-TOF) m/z calcd for [M + 4H]
4+
 
1087.0, found 1086.7. 
 CXCL14 (63-77) 116: Analytical HPLC condition, linear gradient of solvent B 
in solvent A, 5 to 45% over 30 min, retention time = 19.9 min. Preparative HPLC 
condition: linear gradient of solvent B in solvent A, 16 to 26% over 30 min. MS 
(ESI-TOF) m/z calcd for [M + 2H]
2+
 1087.5, found 1087.1. 
 
Synthesis of the disulfide dimer of CXCL14 (52-72) 117 from corresponding 
monomer 118 
 The requisite monomers were prepared using standard Fmoc SPPS in a manner 
almost identical to that employed for CXCL14 (50-77, f,c-EK) 43. The truncated dimers 
were synthesized using the method similar to that employed for N2C 37 with 
corresponding monomer peptides. 
 Dimer of CXCL14 (52-72) 117 (0.96 mg from 118 (1.6 mg, 0.56 mol), 61%): 
Analytical HPLC condition, linear gradient of solvent B in solvent A, 5 to 45% over 30 
min, retention time = 22.7 min. Semi-preparative HPLC condition: linear gradient of 
solvent B in solvent A, 18 to 28% over 30 min. MS (ESI-TOF) m/z calcd for [M + 5H]
5+
 
67 
 
1133.6, found 1133.3. 
 CXCL14 (52-72) 118 (5.4 mg from 50 mg resin, 68%): Analytical HPLC 
condition, linear gradient of solvent B in solvent A, 5 to 45% over 30 min, retention 
time = 21.3 min. Preparative HPLC condition: linear gradient of solvent B in solvent A, 
18 to 28% over 30 min. MS (ESI-TOF) m/z calcd for [M + 3H]
3+
 945.2, found 944.9. 
 
Synthesis of the disulfide dimer of CXCL14 (52-72) with mutation of their 
aromatic amino acid residues to alanine 
 These mutated monomeric peptides were constructed on 
Fmoc-Arg(Pbf)-Alko-PEG resin (loading: 0.22 mmol amino acid/g) using Peptide 
Synthesizer CS336. Fmoc SPPS (Acylation: Fmoc amino acid (4.0 equiv), HBTU (3.8 
equiv) and DIEA (8.0 equiv) in DMF for 1 h; Fmoc removal: 20% (v/v) piperidine in 
DMF for 15 min) was performed for the chain elongation to give protected peptide resin. 
The completed resin was treated with TFA-thioanisole-m-cresol-H2O-EDT (80:5:5:5:5, 
(v/v)) at room temperature for 1.5 h. After filtration of the resin, cooled Et2O was added 
to the filtrate, and the resulting precipitate was collected by centrifugation. The obtained 
precipitate was washed with cold Et2O and purified by preparative HPLC to give 
desired monomer peptides. 
 
The dimer of CXCL14 (52-72, W64A, Y65A) 119 from 120 
 Dimer of CXCL14 (52-72, W64A, Y65A) 119 (0.51 mg from 120 (1.2 mg, 
0.46 mol), 42%): Analytical HPLC condition, linear gradient of solvent B in solvent A, 
5 to 45% over 30 min, retention time = 17.4 min. Semi-preparative HPLC condition: 
linear gradient of solvent B in solvent A, 16 to 26% over 30 min. MS (ESI-TOF) m/z 
calcd for [M + 5H]
5+
 1050.8, found 1050.5. 
 CXCL14 (52-72, W64A, Y65A) 120 (9.0 mg from 50 mg resin, 54%): 
Analytical HPLC condition, linear gradient of solvent B in solvent A, 5 to 45% over 30 
min, retention time = 18.6 min. Preparative HPLC condition: linear gradient of solvent 
B in solvent A, 18 to 28% over 30 min. MS (ESI-TOF) m/z calcd for [M + 4H]
4+
 657.4, 
found 657.3. 
 
The dimer of CXCL14 (52-72, W64A, W68A) 121 from 122 
 Dimer of CXCL14 (52-72, W64A, W68A) 121 (0.51 mg from 122 (1.3 mg, 
0.51 mol), 39%): Analytical HPLC condition, linear gradient of solvent B in solvent A, 
5 to 45% over 30 min, retention time = 16.4 min. Semi-preparative HPLC condition: 
linear gradient of solvent B in solvent A, 12 to 22% over 30 min. MS (ESI-TOF) m/z 
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calcd for [M + 5H]
5+
 1041.6, found 1041.3. 
 CXCL14 (52-72, W64A, W68A) 122 (9.0 mg from 50 mg resin, 48%): 
Analytical HPLC condition, linear gradient of solvent B in solvent A, 5 to 45% over 30 
min, retention time = 15.3 min. Preparative HPLC condition: linear gradient of solvent 
B in solvent A, 10 to 20% over 30 min. MS (ESI-TOF) m/z calcd for [M + 4H]
4+
 652.0, 
found 651.5. 
 
The dimer of CXCL14 (52-72, Y65A, W68A) 123 from 124 
 Dimer of CXCL14 (52-72, Y65A, W68A) 123 (0.51 mg from 124 (0.87 mg, 
0.33 mol), 58%): Analytical HPLC condition, linear gradient of solvent B in solvent A, 
5 to 45% over 30 min, retention time = 18.2 min. Semi-preparative HPLC condition: 
linear gradient of solvent B in solvent A, 16 to 26% over 30 min. MS (ESI-TOF) m/z 
calcd for [M + 5H]
5+
 1050.8, found 1050.6. 
 CXCL14 (52-72, Y65A, W68A) 124 (5.3 mg from 50 mg resin, 30%): 
Analytical HPLC condition, linear gradient of solvent B in solvent A, 5 to 45% over 30 
min, retention time = 17.1 min. Preparative HPLC condition: linear gradient of solvent 
B in solvent A, 12 to 22% over 30 min. MS (ESI-TOF) m/z calcd for [M + 3H]
3+
 876.1, 
found 875.9. 
 
The dimer of CXCL14 (52-72, W64A, Y65A, W68A) 125 from 126 
 Dimer of CXCL14 (52-72, W64A, Y65A, W68A) 125: Analytical HPLC 
condition, linear gradient of solvent B in solvent A, 5 to 45% over 30 min, retention 
time = 15.9 min. Semi-preparative HPLC condition: linear gradient of solvent B in 
solvent A, 10 to 20% over 30 min. MS (ESI-TOF) m/z calcd for [M + 4H]
4+
 1255.7, 
found 1255.2. 
 CXCL14 (52-72, W64A, Y65A, W68A) 126 (7.7 mg from 50 mg resin, 45%): 
Analytical HPLC condition, linear gradient of solvent B in solvent A, 5 to 45% over 30 
min, retention time = 14.8 min. Preparative HPLC condition: linear gradient of solvent 
B in solvent A, 9 to 19% over 30 min. MS (ESI-TOF) m/z calcd for [M + 3H]
3+
 837.8, 
found 837.5. 
 
The dimer of CXCL14 (52-72, F61A) 127 from 128 
 Dimer of CXCL14 (52-72, F61A) 127 (0.29 mg from 128 (0.95 mg, 0.34 
mol), 31%): Analytical HPLC condition, linear gradient of solvent B in solvent A, 5 to 
45% over 30 min, retention time = 20.0 min. Semi-preparative HPLC condition: linear 
gradient of solvent B in solvent A, 18 to 28% over 30 min. MS (ESI-TOF) m/z calcd for 
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[M + 5H]
5+
 1103.2, found 1102.9. 
 CXCL14 (52-72, F61A) 128 (8.5 mg from 50 mg resin, 50%): Analytical 
HPLC condition, linear gradient of solvent B in solvent A, 5 to 45% over 30 min, 
retention time = 18.0 min. Preparative HPLC condition: linear gradient of solvent B in 
solvent A, 16 to 26% over 30 min. MS (ESI-TOF) m/z calcd for [M + 3H]
3+
 919.8, 
found 919.5. 
 
The dimer of CXCL14 (52-72, F61A, W64A) 129 from 130 
 Dimer of CXCL14 (52-72, F61A, W64A) 129 (0.26 mg from 130 (0.95 mg, 
0.36 mol), 27%): Analytical HPLC condition, linear gradient of solvent B in solvent A, 
5 to 45% over 30 min, retention time = 17.1 min. Semi-preparative HPLC condition: 
linear gradient of solvent B in solvent A, 17 to 27% over 30 min. MS (ESI-TOF) m/z 
calcd for [M + 5H]
5+
 1057.2, found 1056.9. 
 CXCL14 (52-72, F61A, W64A) 130 (9.0 mg from 50 mg resin, 56%): 
Analytical HPLC condition, linear gradient of solvent B in solvent A, 5 to 45% over 30 
min, retention time = 16.1 min. Preparative HPLC condition: linear gradient of solvent 
B in solvent A, 11 to 21% over 30 min. MS (ESI-TOF) m/z calcd for [M + 3H]
3+
 881.5, 
found 881.2. 
 
The dimer of CXCL14 (52-72, F61A, Y65A) 131 from 132 
 Dimer of CXCL14 (52-72, F61A, Y65A) 131 (0.41 mg from 132 (1.0 mg, 0.38 
mol), 41%): Analytical HPLC condition, linear gradient of solvent B in solvent A, 5 to 
45% over 30 min, retention time = 19.4 min. Semi-preparative HPLC condition: linear 
gradient of solvent B in solvent A, 17 to 27% over 30 min. MS (ESI-TOF) m/z calcd for 
[M + 5H]
5+
 1066.4, found 1066.2. 
 CXCL14 (52-72, F61A, Y65A) 132 (8.7 mg from 50 mg resin, 48%): 
Analytical HPLC condition, linear gradient of solvent B in solvent A, 5 to 45% over 30 
min, retention time = 18.0 min. Preparative HPLC condition: linear gradient of solvent 
B in solvent A, 17 to 27% over 30 min. MS (ESI-TOF) m/z calcd for [M + 4H]
4+
 667.1, 
found 667.0. 
 
The dimer of CXCL14 (52-72, F61A, W68A) 133 from 134 
 Dimer of CXCL14 (52-72, F61A, W68A) 133 (0.63 mg from 134 (1.2 mg, 0.44 
mol), 55%): Analytical HPLC condition, linear gradient of solvent B in solvent A, 5 to 
45% over 30 min, retention time = 17.3 min. Semi-preparative HPLC condition: linear 
gradient of solvent B in solvent A, 15 to 25% over 30 min. MS (ESI-TOF) m/z calcd for 
70 
 
[M + 4H]
4+
 1321.2, found 1320.8. 
 CXCL14 (52-72, F61A, W68A) 134 (8.6 mg from 50 mg resin, 58%): 
Analytical HPLC condition, linear gradient of solvent B in solvent A, 5 to 45% over 30 
min, retention time = 16.5 min. Preparative HPLC condition: linear gradient of solvent 
B in solvent A, 12 to 22% over 30 min. MS (ESI-TOF) m/z calcd for [M + 3H]
3+
 881.5, 
found 881.3. 
 
The dimer of CXCL14 (52-72, F61A, W64A, Y65A) 135 from 136 
 Dimer of CXCL14 (52-72, F61A, W64A, Y65A) 135 (0.37 mg from 136 (1.2 
mg, 0.46 mol), 32%): Analytical HPLC condition, linear gradient of solvent B in 
solvent A, 5 to 45% over 30 min, retention time = 16.5 min. Semi-preparative HPLC 
condition: linear gradient of solvent B in solvent A, 8 to 18% over 30 min. MS 
(ESI-TOF) m/z calcd for [M + 5H]
5+
 1020.3, found 1020.2. 
 CXCL14 (52-72, F61A, W64A, Y65A) 136 (8.3 mg from 50 mg resin, 60%): 
Analytical HPLC condition, linear gradient of solvent B in solvent A, 5 to 45% over 30 
min, retention time = 15.8 min. Preparative HPLC condition: linear gradient of solvent 
B in solvent A, 10 to 20% over 30 min. MS (ESI-TOF) m/z calcd for [M + 3H]
3+
 850.8, 
found 850.6. 
 
The dimer of CXCL14 (52-72, F61A, W64A, W68A) 137 from 138 
 Dimer of CXCL14 (52-72, F61A, W64A, W68A) 137 (0.54 mg from 138 (1.2 
mg, 0.47 mol), 46%): Analytical HPLC condition, linear gradient of solvent B in 
solvent A, 5 to 45% over 30 min, retention time = 15.0 min. Semi-preparative HPLC 
condition: linear gradient of solvent B in solvent A, 10 to 20% over 30 min. MS 
(ESI-TOF) m/z calcd for [M + 5H]
5+
 1011.1, found 1011.0. 
 CXCL14 (52-72, F61A, W64A, W68A) 138 (5.6 mg from 50 mg resin, 44%): 
Analytical HPLC condition, linear gradient of solvent B in solvent A, 5 to 45% over 30 
min, retention time = 14.1 min. Preparative HPLC condition: linear gradient of solvent 
B in solvent A, 8 to 18% over 30 min. MS (ESI-TOF) m/z calcd for [M + 3H]
3+
 843.1, 
found 843.0. 
 
The dimer of CXCL14 (52-72, F61A, Y65A, W68A) 139 from 140 
 Dimer of CXCL14 (52-72, F61A, Y65A, W68A) 139 (0.48 mg from 140 (1.0 
mg, 0.41 mol), 47%): Analytical HPLC condition, linear gradient of solvent B in 
solvent A, 5 to 45% over 30 min, retention time = 16.8 min. Semi-preparative HPLC 
condition: linear gradient of solvent B in solvent A, 12 to 22% over 30 min. MS 
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(ESI-TOF) m/z calcd for [M + 5H]
5+
 1020.3, found 1020.2. 
 CXCL14 (52-72, F61A, Y65A, W68A) 140 (3.6 mg from 50 mg resin, 26%): 
Analytical HPLC condition, linear gradient of solvent B in solvent A, 5 to 45% over 30 
min, retention time = 15.5 min. Preparative HPLC condition: linear gradient of solvent 
B in solvent A, 13 to 19% over 30 min. MS (ESI-TOF) m/z calcd for [M + 3H]
3+
 850.8, 
found 850.6. 
 
The dimer of CXCL14 (52-72, F61A, W64A, Y65A, W68A) 141 from 142 
 Dimer of CXCL14 (52-72, F61A, W64A, Y65A, W68A) 141: Analytical 
HPLC condition, linear gradient of solvent B in solvent A, 5 to 45% over 30 min, 
retention time = 14.4 min. Semi-preparative HPLC condition: linear gradient of solvent 
B in solvent A, 8 to 18% over 30 min. MS (ESI-TOF) m/z calcd for [M + 5H]
5+
 974.3, 
found 974.1. 
 CXCL14 (52-72, F61A, W64A, Y65A, W68A) 142 (4.9 mg from 50 mg resin, 
40%): Analytical HPLC condition, linear gradient of solvent B in solvent A, 5 to 45% 
over 30 min, retention time = 13.3 min. Preparative HPLC condition: linear gradient of 
solvent B in solvent A, 7 to 17% over 30 min. MS (ESI-TOF) m/z calcd for [M + 3H]
3+
 
812.4, found 812.3. 
 
Synthesis of the disulfide dimers of CXCL14 (52-72) with mutation of its b- or 
f-position to alanine 
 The requisite monomers were prepared using the Fmoc SPPS with the use of 
Peptide Synthesizer CS336 mentioned above (b to Ala) or standard Fmoc SPPS in a 
fashion similar to that employed for C-terminal Fr 3 (f to Ala), respectively. The 
mutated deletion dimers were synthesized using the method almost identical to that 
employed for N2C 37 with corresponding monomer peptides. 
 
The dimer of CXCL14 (52-72, b to Ala) 143 from 144 
 Dimer of CXCL14 (52-72, b to Ala) 143 (0.71 mg from 144 (1.4 mg, 0.51 
mol), 51%): Analytical HPLC condition, linear gradient of solvent B in solvent A, 5 to 
45% over 30 min, retention time = 21.4 min. Semi-preparative HPLC condition: linear 
gradient of solvent B in solvent A, 18 to 28% over 30 min. MS (ESI-TOF) m/z calcd for 
[M + 5H]
5+
 1082.7, found 1082.5. 
 CXCL14 (52-72, b to Ala) 144 (5.2 mg from 50 mg resin, 39%): Analytical 
HPLC condition, linear gradient of solvent B in solvent A, 5 to 45% over 30 min, 
retention time = 20.0 min. Preparative HPLC condition: linear gradient of solvent B in 
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solvent A, 18 to 28% over 30 min. MS (ESI-TOF) m/z calcd for [M + 3H]
3+
 902.8, 
found 902.6. 
 
The dimer of CXCL14 (52-72, f to Ala) 145 from 146 
 Dimer of CXCL14 (52-72, f to Ala) 145 (0.18 mg from 146 (1.4 mg, 0.52 
mol), 13%): Analytical HPLC condition, linear gradient of solvent B in solvent A, 5 to 
45% over 30 min, retention time = 24.5 min. Semi-preparative HPLC condition: linear 
gradient of solvent B in solvent A, 20 to 30% over 30 min. MS (ESI-TOF) m/z calcd for 
[M + 5H]
5+
 1067.2, found 1067.0. 
 CXCL14 (52-72, f to Ala) 146 (5.5 mg from 50 mg resin, 39%): Analytical 
HPLC condition, linear gradient of solvent B in solvent A, 5 to 45% over 30 min, 
retention time = 23.2 min. Preparative HPLC condition: linear gradient of solvent B in 
solvent A, 19 to 29% over 30 min. MS (ESI-TOF) m/z calcd for [M + 3H]
3+
 889.8, 
found 889.5. 
 
Binding assays with 
125
I-labeled CXCL14 
CXCL14 was labeled with 
125
I by Bolton-Hunter reagent. Briefly, recombinant 
human CXCL14 (5 g) was suspended in 50 L of 0.1 M borate buffer (pH 8.2) 
containing 0.01% Tween 20. The mixture was reacted with Bolton-Hunter reagent [
125
I] 
(9.25 MBq) and incubated on ice for 2 h. The reaction mixture was applied to a D-Salt 
polyacrylamide desalting column with a 1.8 K molecular weight cut off and highly 
radioactive fractions (~ 2 mL) were saved as 
125
I-labeled CXCL14. 
Binding assays were carried out according to the previously described 
method.
15
 In brief, 5 × 10
5
 cells were suspended in 50 L RPMI1640 containing 0.1% 
fatty acid-free BSA and 20 mM HEPES (pH 7.5) and incubated on ice for 2 h with 50 
L 10 nM 125I-labeled CXCL14 in the presence or absence of 100 nM competitor. Cells 
were centrifuged at 7,500 × g on a 150 L oil cushion in a 400 L polyethylene tube. 
Radioactivity in the tip fragment was measured using a WIZARD2 gamma counter. 
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